Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review)

HONGYI LI1*, YU LIU1*, YANG WANG2, XIA ZHAO1 and XIAORONG QI1

1Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children and Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University; 2Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Received April 28, 2021; Accepted August 4, 2021

DOI: 10.3892/or.2021.8174

Abstract. Ovarian cancer (OC) remains the leading cause of mortality due to gynecological malignancies. Epidemiological studies have demonstrated that steroid hormones released from the hypothalamic-pituitary-ovarian axis can play a role in stimulating or inhibiting OC progression, with gonadotropins, estrogens and androgens promoting OC progression, while gonadotropin-releasing hormone (GnRH) and progesterone may be protective factors in OC. Experimental studies have indicated that hormone receptors are expressed in OC cells and mediate the growth stimulatory or growth inhibitory effects of hormones on these cells. Hormone therapy agents have been evaluated in a number of clinical trials. The majority of these trials were conducted in patients with relapsed or refractory OC with average efficacy and limited side-effects. A better understanding of the mechanisms through which hormones affect cell growth may improve the efficacy of hormone therapy. In the present review article, the role of hormones (GnRH, gonadotropins, androgens, estrogens and progestins) and their receptors in OC tumorigenesis, and hormonal therapy in OC treatment is discussed and summarized.

1. Introduction

Ovarian cancer (OC) is a highly common malignancy of the female reproductive system that ranks 4th among all causes of cancer-related mortality among women (1,2). The early symptoms of OC are atypical, and reliable methods in terms of early detection are insufficient, with ~70% of cases already presenting with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease at clinical diagnosis (3). OC is currently treated with full-stage surgery or tumor cell reduction combined with first-line chemotherapy drugs (paclitaxel or platinum) as the standard of care. Chemotherapy results in first remission in ~80% of patients, whereas the majority of cases experience tumor recurrence and progressive chemoresistance within 5 years, achieving a 5-year survival rate of <47.6% (3). Thus, further investigations are required in order to gain insight into the pathogenesis OC and design novel therapeutic strategies.

OC is divided into various histopathological subtypes, including epithelial, germ cell and sex cord-stromal tumors. Almost 90% of malignant ovarian tumors are epithelial, originating in the ovarian surface epithelium (OSE). However, over the past few years, the fimbriae of the fallopian tubes were considered as the probable site of origin of such malignancies, particularly high-grade serous OC (HGSOC) (4,5). It is noteworthy that simple original OSE exhibiting mesenchyme-related characteristics is characterized by the Müllerian epithelium since its development towards malignancy. Based
Moreover, the pathogenesis of OC is also associated with noticeably increase the risk of developing mucinous OC (12,13). Endometrioid and clear cell OC may be associated with genes involved in homologous recombination DNA repair (e.g., BRCA1 and BRCA2) (9,10). LGSOC may be implicated in the activation of the MAPK pathway via NRAS, KRAS or BRAF mutations, and is associated with high levels of estrogen receptor (ER) and progesterone receptor (PR) expression (11). Endometrioid and clear cell OC may be associated with endometriosis, whereas certain lifestyle factors (e.g., smoking) noticeably increase the risk of developing mucinous OC (12,13).

Moreover, the pathogenesis of OC is also associated with mutations in the AT-rich interaction domain 1A (ARID1A), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PI3CA) and phosphatase and tensin homolog (PTEN) genes (14–16). Ovarian germ cell tumors develop from primordial germ cells of the embryonic gonads, and the most common germ cell malignancies include yolk sac tumor, teratoma and dysgerminoma. Sex cord-stromal neoplasms may originate from a wide range of cell types within the sex cords and gonadal stroma. Granulosa cell tumors (GCTs) are the most common in this group, accounting for ~5% of all OC cases.

Despite its major impact on public health, the factors regulating the development and progression of OC have yet to be fully elucidated (17,18). In general, women who inherit mutations in either one of the two breast cancer susceptibility genes (BRCA1 or BRCA2) are at an increased risk of developing breast cancer and OC compared with women without a BRCA gene mutation. The overall lifetime risk for developing OC is 20–40% for women who have a BRCA1 mutation and 10–20% for women who have a BRCA2 mutation. Women in the general population have a <2% risk of developing OC (19). The National Comprehensive Cancer Network (NCCN) OC guidelines (2021) (20) recommend poly(ADP-ribose) polymerase (PARP) inhibitors for maintenance therapy in patients with platinum-sensitive recurrent OC, regardless of the biomarker status. In addition, the widespread application of hormone therapy in the clinical treatment of breast and endometrial cancers has made hormone receptors the primary research direction for a targeted cure for OC (21,22). It has been clearly stated in the NCCN OC guidelines (2021) (20) and in the European Society of Medical Oncology/European Society of Gynecological Oncology guidelines (23) that hormonal therapy may be used to treat patients with platinum-resistant and recurrent OC. Epidemiological studies have demonstrated that steroid hormones released through the hypothalamic-pituitary/ovarian axis (Fig. 1). Experimental studies and clinicopathological findings have demonstrated that hormone receptors are expressed in the normal ovarian surface epithelium, as well as in ovarian cancer cells and mediate the stimulatory or inhibitory effects of various hormones on the development of these cells. Moreover, hormonal therapeutic agents have been clinically evaluated in some patients with recurrent or refractory ovarian tumors, mainly exhibiting average efficiency and limited side-effects. For example, in the study by Sieh et al (25), data from almost 3,000 women with invasive EOC were analyzed using hormone receptor assay and evidence of the prognostic role of ER and PR and the potential hormonal sensitivity of EOC was provided. In addition, Paleari and DeCensi (26) conducted a meta-analysis of 53 clinical trials, including 2,490 patients and revealed an overall clinical benefit rate (CBR) of 41% [95% confidence interval (CI), 0.34–0.48] for any endocrine therapy. These results suggest that a greater understanding of the mechanisms through which hormones affect OC cell development may improve the effectiveness of hormone therapy for patients with this type of cancer.

The present review conducted a literature search on PubMed, Web of Science and Clinical Trials for relevant articles published from inception to May, 2021 with no restrictions. The search terms included ‘hormone therapy’ or ‘hormone replacement therapy’ and ‘ovarian cancer’ or ‘ovarian carcinoma’ or ‘ovary cancer’; ‘peptide hormones (gonadotropin-releasing hormone/GnRH, gonadotropins, androgens, estrogens, and progestins) and ‘ovarian cancer’ or ‘ovarian carcinoma’ or ‘ovary cancer’). The reference lists of the included studies were also reviewed for potential available studies. The mechanisms involved in the hormonal influences on the progression of OC (mainly EOC) are summarized, mentioning peptide hormones (GnRH, gonadotropins, androgens, estrogens and progestins), and the clinical efficacy and safety of various hormonal therapies for OC are discussed.

2. Hormone hypothesis of ovarian cancer pathogenesis

Epidemiological studies have implicated hormonal and reductive factors in the pathogenesis of OC. Several hormonal hypotheses have been suggested thus far in an attempt to elucidate the etiology of OC, including gonadotropin signaling, direct influences exerted by progesterone and androgen, and incessant ovulation (Fig. 2). The first hypothesis of sex hormones as a potential mechanism underlying ovarian carcinogenesis is the ‘gonadotropin hypothesis’ (27-29). According to this hypothesis, OC advances due to excessive ovarian tissue excitation by pituitary gonadotropins [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)] (27). Exposure to excess gonadotropins, which is associated with menopause, ovulation or infertility treatment, has been identified as an important risk factor for the development of OC. Moreover, such a theory would also explain the decreased risk of developing OC associated with the use of oral contraceptives and pregnancy, which results in the decreased exposure to gonadotropins owing to the negative feedback regulation of steroid hormones onto the pituitary gland (30,31). In contrast to the above, post-menopausal women with increased gonadotropin levels and women suffering from polycystic ovary syndrome (PCOS), who have upregulated circulating LH levels, are at an
increased risk of developing EOC (32). Evidence from several epidemiological studies supports the gonadotropin theory. First, the rise in circulating gonadotropin levels exhibits a strong temporal association with the increased incidence of EOC (33,34). Menopause occurs at the age of ~51 years and is accompanied by variations in gonadotropin levels due to the cessation of the menstrual cycle and the deterioration of ovarian function. When ovarian function ceases completely, the negative feedback of ovarian steroids on gonadotropins is lost. Within 2-3 years following menopause, the gonadotropin levels can be particularly high. Accordingly, the LH and FSH concentrations may peak 3-4-fold (20-50 mIU/ml) and 10-20-fold (50-100 mIU/ml) compared with the values during the proliferation stage of the menstrual cycle, respectively. Subsequently, the levels of both gonadotropins slightly decline in a gradual manner. The incidence of EOC markedly increases at the age range in which the majority of women experience menopause, a phenomenon consistent with the gonadotropin theory. The mean age at onset of EOC is 57-59 years in the USA, and half of the cases are aged >65 years at the time of diagnosis, with 85-90% of the cases recorded in peri- or post-menopausal women, whereas EOC occurs in only 10-15% of pre-menopausal women (35,36). According to early information, multiple pregnancies and the use of oral contraceptives are established protective factors in terms of the incidence of EOC; each additional pregnancy is associated with a 10-16% reduction in the risk of developing EOC (37,38), and the protective effect of oral contraceptives increases by 7% with each year of use, reaching a 80% decrease among long-term users (over a decade) (39). These data regarding multiple pregnancies and the long-term use of oral contraceptives support the gonadotropic theory, since these factors are associated with low gonadotropin levels and the suppression of incessant ovulation. Furthermore, late menopause and early menarche are associated with a higher number of ovulations and exposure to high gonadotropin levels, thereby increasing the risk of developing EOC. The gonadotropin hypothesis is further supported by the elevated gonadotropin levels found in the cysts and peritoneal fluid of patients with EOC (40,41). In particular, high concentrations of FSH in ascitic fluid have been suggested to be inversely associated with survival (42), and EOC has been found to be associated with significantly higher levels of FSH in serum and capsular fluid compared with non-neoplastic ovarian lesions (43).

Another major hypothesis in the development of EOC, namely incessant ovulation, was proposed in 1971 by Fathalla (44). The causal mechanism through which ovulation facilitates ovarian carcinogenesis remains unclear; however, some possible theories have been suggested. During the ovulatory process, the OSE is damaged and, subsequently, the repair process occurs through extensive cell proliferation, increasing the likelihood of spontaneous error and genome instability during DNA replication (45). Later studies under various disciplines proved the protective effect exerted by oral contraceptives, provided further insight into the biological mechanisms of ovulation, examined the possible pharmacological production of luteinized unruptured follicles and presented epidemiology-related evidence for this hypothesis (30,46). The lifetime number of ovulatory cycles or years exhibits a positive association with the risk of developing EOC, which supports the hypothesis of incessant ovulation (47,48). The levels of several inflammatory mediators (e.g., prostaglandins and cytokines) are increased during ovulation and may enhance mutagenesis (45). Moreover, the ‘androgen/progestin hypothesis’ is suggested to be a fundamental mechanism underlying the development of EOC. According to this hypothesis, the higher androgen levels observed in menopausal or obese women, and in patients with PCOS, are associated with an increased risk of developing EOC, whereas progesterone reduces the risk of developing EOC (49,50). Although several in vitro and animal studies have suggested a role for androgens in the development of EOC (50-52), the epidemiological evidence is not convincing.

3. Gonadotropins and GnRH

Role of FSH, LH and their receptors in OC and the normal ovarian surface epithelium. The two gonadotropins, FSH and LH, which share similar chemical and structural characteristics, are synthesized in the anterior pituitary, regulate gametogenesis and steroidogenesis in the testes and the ovary in an endocrine manner, and they are critical regulators of ovarian cell function (53). Specific receptors for gonadotropins have been reported in EOC, as well as in normal OSE cells and in fallopian tube cells (54,55). The LH receptor (LHR) and FSH receptor (FSHR) are G-protein coupled seven-transmembrane...
domain receptors (Fig. 3) that are highly expressed in theca and granulosa cells, and play essential roles in reproductive physiology when activated by their respective hormones (56).

Over the past few years, FSHR expression has been identified in the tumor vasculature of a number of epithelial tumors, indicating a wider role for FSHR in carcinogenesis (57,58).
The expression status of various gonadotropin receptors likely affects ovarian tumor progression through various mechanisms. According to Lenhard *et al* (59), patients with EOC expressing higher levels of FSHR than LHR had a worse prognosis, whereas cases expressing higher levels of LHR than FSHR exhibited an improved overall survival. Two previous studies investigated the effects of FSHR overexpression on immortalized OSE cells or benign ovarian epithelial tumor cells and the advanced EOC cell line, OVCAR-3 (60,61). According to these studies, FSHR overexpression may be associated with an increased oncogenic potential and the increased proliferation of pre-neoplastic OSE cells. In addition, EOC cells that expressed FSHR exhibited a superior invasive ability (61). These data indicate that FSHR may activate oncogenic pathways that promote cell proliferation and invasive phenotypes, even in the absence of FSH. Data from another study demonstrated that there was a positive association between FSHR and aryl hydrocarbon receptor levels, with their simultaneous expression observed in patients with the least favorable EOC outcomes (62). Cheung *et al* (63) investigated the functional roles of gonadotropin receptor expression in the progression of EOC and demonstrated that the knockdown of FSHR and LHR expression was associated with a more aggressive EOC phenotype and promoted pro-metastatic behavior. The effects exerted by gonadotropins on EOC have not yet been thoroughly investigated. Some studies have demonstrated that gonadotropins (FSH and LH) promote cell migration and invasion by inducing cyclooxygenase (COX)2 expression in EOC cells, and that specific COX2 inhibitors significantly prevent these effects (53,64). A recent study reported that sphingosine kinase (SphK) served as a key mediator of FSH-induced EOC cell proliferation, suggesting a novel strategy of using two isozymes of SphK as drug targets for the treatment of EOC (65). By contrast, another study demonstrated that in SKOV-3 cells, the overexpression of LHR upregulated the expression of *ERBB2*, and the addition of LH further increased *ERBB2* expression, whereas it reduced cell proliferation and motility, indicating that the upregulation of *ERBB2* independently failed to effectively decrease the anti-proliferative effect exerted by LH on these cells (66). LH has also been implicated in the development of EOC by inducing the secretion of VEGF via the PI3K/AKT/mTOR pathway (67) and upregulating survivin expression, leading to the inhibition of apoptosis (68).

**GnRHs and their receptors in OC.** GnRH is a decapeptide hormone synthesized by the hypothalamus and comprises 10 different amino acid residues. As a key neuromodulator of the reproductive system, GnRH is secreted in pulses and enters the anterior lobe of the pituitary gland via the hypothalamic/pituitary portal circulation, acts on gonadotropin-secreting cells in the anterior pituitary, and regulates gamete formation and sex hormone production in the gonads through the regulation of pituitary synthesis and the secretion of FSH and LH. At present, there are three forms of GnRH found in most vertebrates, namely GnRH-I, GnRH-II and GnRH-III, of which two subtypes, GnRH-I and GnRH-II, are expressed in humans (69,70). GnRH-I, also known as LH-releasing hormone, plays a role in regulating ovarian proliferative activity. GnRH-I and its receptor are expressed in ~80% of human ovarian epithelial tumors, EOC cell lines and OSE cells (71), and their activation by exogenous factors has been found to be associated with the notable (time- and dose-dependent) and specific inhibition of cell proliferation (72). Currently, the protein expression of the GnRH-I receptor is considered as a favorable prognostic factor in primary ovarian tumors (73,74). GnRH-II has been identified in the hypothalamus of chickens and has been reported to exhibit a conserved structure in vertebrates. Similar to GnRH-I, GnRH-II is expressed within a wide range of human ovarian cells, including OSE cells, granulosa luteinizing cells, as well as in EOC cells (75-77). It has been suggested that the anti-proliferative effects of GnRH-II on tumor cells are mediated via the GnRH-I receptor, as a functional GnRH-II receptor has not yet been identified (78). Further research on GnRH has demonstrated that, apart from the pituitary gland and hypothalamus, GnRH and the relevant receptors are also expressed in peripheral tissues (e.g., the ovaries, placenta, endometrium and smooth muscle) and in certain malignant tumors (e.g., OC, endometrial, breast and prostate cancers). GnRH must bind to the high-affinity GnRH receptor (GnRH-R) to exert its effects, i.e., the regulation of pituitary hormone release and extra-pituitary products.

**Possible mechanisms of GnRH/GnRH analog (GnRH-a) therapy for OC.** GnRH-as are produced by replacing or removing the 6th and 10th amino acids from naturally occurring GnRH, and their biological properties are 50-100-fold stronger compared with those of natural GnRH. The ultimate effects and efficacy of GnRH agonists and antagonists are similar, differing in that antagonists have a more rapid onset of action and do not have the initial surge in sex hormone release. For example, the GnRH-a, degarelix, which is an antagonist of gonadotropin receptors in the pituitary gland, directly inhibits the synthesis and release of LH and FSH, and does not have the initial surge characteristic of GnRH agonists (79). In addition to protecting ovarian function and improving the quality of life of patients, GnRH-as may also act as antitumor agents through various mechanisms. GnRH agonists and antagonists act by binding to GnRH-Rs and are used in the treatment of steroid-dependent conditions, including hormone-dependent tumors (80). The pharmacological application of GnRH or the relevant synthetic analogs (agonists and antagonists) may represent a valuable tool for stimulating or blocking gonadotropin secretion, regulating the fertility of women suffering from reproductive disorders and assisting with reproductive technologies (81). GnRH-as can inhibit the hypothalamic/pituitary axis and inhibit tumor growth by downregulating FSH and LH secretion and by binding to GnRH-I and GnRH-II receptors on the surface of cancer cells, thereby exerting direct inhibitory effects on cancer cells through the regulation of local autocrine and paracrine secretion (Table 1). Following the administration of GnRH agonists, FSH and LH levels are increased for a short period of time; following long-term administration, the number of GnRH-Rs decreases, inhibiting FSH and LH release and thus, the secretion of estrogen and progesterone by the ovaries. GnRH antagonists exert opposite effects. By directly binding to the GnRH-R, they inhibit the release of FSH and LH without stimulating the pituitary gland, thereby reducing the level of progesterone and estrogen in the blood, and inhibiting sex hormone-dependent tumor.
development (82). GnRH does not only play a key role in mammalian reproductive regulation; however, it has also been widely reported to exert significant antitumor (anti-proliferative and anti-metastatic) effects by regulating the activation of local GnRH-R (83,84). The antitumor mechanisms of action of GnRH-I in OC are considered to involve the desensitization or downregulation of GnRH-I receptors within the pituitary gland, thereby reducing gonadotropin secretion, which in turn leads to a decrease in gonadotropin steroids acting as tumor growth-promoting factors (85,86). In addition to regulating gonadotropin and relevant receptors in vitro, GnRH-I and the relevant analogs have also been found to exert a direct inhibitory effect on normal epithelial cells and EOC cell lines in vitro and in vivo, leading to cell cycle arrest based on the increase in the protein levels of p53 and p21 (87).

After binding to G-protein α(i), activated GnRH-R induces a phosphotyrosine phosphatase (PTP) that is subject to EGF-triggered tyrosine autophosphorylation of the EGF receptor, which leads to a reduction in cell proliferation and mitogenic signal transduction (88). This process prevents growth factor-driven mitogenic signaling, leading to the EGFR-induced expression of MAPK (72) and c-fos (89), as well as in the inhibition of cell proliferation (90). In addition, GnRH-I has been reported to have the ability to trigger JunD-DNA binding, leading to an increased cell number and a decreased DNA synthesis at the G0/G1 phase of the cell cycle, thereby reducing cell proliferation (91). The GnRH-I analog, leuprorelin, may also induce the apoptosis of tumor cells through the Fas-ligand/Fas mechanism. Data from two research teams suggested that elevated levels of Fas ligand in tumors expressing GnRH-R were likely to promote apoptotic cell death by targeting intratumoral Fas-positive cells, thereby exerting growth inhibitory effects on GnRH-sensitive tumors (92,93). However, the GnRH-I agonist, triptorelin (D-Trp-6-LH-RH), has been reported to reduce apoptosis induced by NF-κB activation triggered by the cytotoxic

---

Table I. Hormonal therapy options for ovarian cancer.

| Hormone therapy | Mechanisms | Options |
|-----------------|------------|---------|
| GnRH analogs    | Competitively binds GnRH-R and reduces the secretion of FSH and LH | GnRH I agonists |
|                 |            | Triptorelin |
|                 |            | Goserelin |
|                 |            | Histrelin |
|                 |            | Leuprolide acetate |
|                 |            | GnRH II antagonists |
|                 |            | Cetrorelix |
|                 |            | Degarelix acetate |
| Estrogen        | Estrogen receptor blockade | Antiestrogens: |
|                 |            | Tamoxifen |
|                 |            | Toremifene |
|                 | Estrogen synthesis suppression | Aromatase inhibitors: |
|                 |            | Anastrozole |
|                 |            | Exemestane |
|                 |            | Letrozole |
|                 | Estrogen receptor downregulation | ER antagonist: |
|                 |            | Fulvestrant |
|                 |            | Surgery |
|                 | Hormonal ablation | Radiation (infrequently used) |
| Androgen        | Androgen receptor blockade | Anti-androgens: |
|                 |            | Flutamide |
|                 |            | Bicalutamide |
|                 |            | Enzalutamide |
| Progesterone     | Progesterone receptor blockade | PR antagonists: |
|                 |            | Mifepristone |
|                 | Increasing progesterone levels | Medroxyprogesterone |
|                 |            | Megestrol acetate |
|                 |            | Oral contraceptive pills |
|                 |            | Pregnancy |
|                 |            | Breastfeeding |

GnRH-R, gonadotropin-releasing hormone receptor; FSH, follicle-stimulating hormone; LH, luteinizing hormone; ER, estrogen receptor; PR, progesterone receptor.
agent, doxorubicin (94-96). GnRH-II has been reported to exert a more prominent anti-proliferative effect on EOC cells compared with equimolar concentrations of GnRH-I agonists. The inhibitory effect exerted by GnRH-II on the proliferation of EOC cells in humans notably exceeds that exerted by the highly active GnRH-I agonist, triptorelin (97). GnRH-I and GnRH-II agonists inhibit the mitogenic signaling of growth factor receptors based on the activation of PTP, thus leading to decreased proliferation of cancer cells (88). Unlike GnRH-I and GnRH-II agonists, GnRH-II antagonists mainly promote the apoptosis of EOC cells (97). Apoptosis triggered by GnRH-II antagonists occurs through intrinsic apoptotic pathways: This is mediated via the activity of the pro-apoptotic protein, Bax, induced by MAPKs p38 and JNK, followed by caspase-3 activation, the release cytoplasmic cytochrome c, and the probable loss of mitochondrial membrane potential (97,98). The aforementioned antitumor effects were confirmed in nude mice, as a previous study demonstrated that antagonistic analogs of GnRH-II significantly reduced the growth of mouse EOC xenograft tumors without notable side-effects (97). Since the existence of a GnRH-II receptor in humans is controversial, there is a tendency to infer that the anti-proliferative effects of both GnRH-I and GnRH-II are mediated through the GnRH-I receptor (99,100). Of note, the GnRH antagonist, AEZ-115, has exhibited substantial antitumor activity in endometrial and EOC cells; however, this antitumor effect is not mediated by tumor GnRH-Rs (90). Based on the GnRH-R tumor-specific signaling in gynecological cancers, such as OC, and the particular distribution of GnRH-R, gene therapy by employing GnRH-a as inducers of therapeutically related gene transcription has been successfully developed and tested in vitro, as well as in athymic mice with EOC cell xenografts (101).

**Clinical application of GnRH-as in OC.** The inhibitory effect of gonadotropins and the anti-proliferative effect exerted by GnRH-a binding to the receptor form the rationale for their use in various hormone-dependent tumors. In a limited number of clinical studies, GnRH-I agonists have been assessed for their potential as third-line therapy in women with recurrent (mostly platinum-resistant) and refractory OC, and with the failure of at least one regimen of chemotherapy. A summary of 18 clinical trials (102-119), dating back to 1988, that have employed a wide range of GnRH-as (triptorelin, goserelin and leuprolide) for the treatment of patients with relapsed/platinum-resistant OC is presented in Table II. Initially, Parmar et al (102,120) reported on patients with advanced EOC who relapsed following conventional treatment and were treated with slow-release triptorelin microcapsules once per month. During treatment, they observed stable disease (SD) in 5 patients and evidence of clinical and/or radiological partial remission (PR) in 6 patients, where the tumor size decreased by >50%. This result suggests that the clinical benefit of therapy with GnRH agonists for recurrent OC is highly encouraging. Subsequently, based on the inhibition of LH/FSH secretion by GnRH agonists, several clinical trials using triptorelin and leuprolide acetate in advanced recurrent EOC demonstrated associated objective remission and/or disease stabilization in 10-50% of patients (103,112,113,117). In addition, in 2014, 42 women suffering from platinum-refractory or -resistant GnRH-R-positive EOC were evaluated for zoetarel in efficacy and toxicity: of these 42 patients, 6 (14.3%) achieved a partial response and 16 (38%) had SD (121). However, regardless of the aforementioned encouraging results, the benefits of employing GnRH-a as a treatment for advanced OC remain controversial.

A prospective, double-blind, randomized clinical research was carried out to assess whether the addition of the GnRH agonist, triptorelin, to the course of common platinum-based chemotherapy prolongs the survival of patients with stage III or IV EOC who have previously undergone surgery; however, that study reported that the use of triptorelin to inhibit the release of gonadotropins did not inhibit disease progression or prolong the overall survival of the patients (107). In 2001, the European Organization for Research and Treatment of Cancer completed the largest trial of a GnRH agonist to date. In that study, 74 women with progressive OC who were treated with platinum-based chemotherapy received intramuscular injections of the GnRH agonist triptorelin. However, according to the results presented, triptorelin treatment was only moderately effective in patients already treated with platinum-based chemotherapy (106). In a recent phase II clinical trial, tamoxifen and goserelin were combined to treat patients with advanced EOC who had developed recurrence following chemotherapy. Although 'endocrine responses' were observed in ~50% of the patients, including SD (38.5%), partial response (7.7%) and complete response (3.8%), there was no consistent association observed between LH/FSH suppression and tumor progression (111). Similarly, in two other pilot studies in which patients with advanced OC were treated independently with platinum-containing chemotherapy or chemotherapy plus triptorelin, no significant differences were observed between the two groups in terms of drug response, survival and time to progression (122,123). The ineffectiveness of GnRH agonists when combined with chemotherapeutic agents may be due to their direct anti-proliferative effect being neutralized by chemotherapy-related anti-apoptotic activity, as confirmed by in vitro cell experiments. By contrast, Rzepka-Górska et al (124) reported that the combination of chemotherapy and the GnRH-a, goserelin, yielded favorable results in advanced OC and, in that study, patients in the combination group exhibited higher overall and 5-year survival rates compared with the chemotherapy group; in addition, serum LH levels were significantly lower in the combination group. Based on this result, it was concluded that combination therapy for advanced OC was effective and that GnRH-a may be an effective adjuvant therapy for OC (124).

As GnRH agonists have failed to meet the expectations in the clinical setting, the application of high doses of GnRH antagonists warrants further in-depth investigations. Since GnRH-I antagonists do not possess intrinsic gonadotropin activity, the initial 'burst' phenomenon observed with agonist therapy can be avoided, which renders antagonists more tolerable and blocks gonadotropin secretion within a short period of time. High-dose cetrorelix, a GnRH-I antagonist, was used in a phase II trial for the treatment of OC or Müllerian tumors refractory to platinum chemotherapy: All cases who relapsed following standard chemotherapy received 10 mg cetrorelix daily. A total of 3 patients (18%) experienced partial remission following cetrorelix treatment, lasting for 9, 16 and 17 weeks, respectively, and 6 patients (35%) had SD for 1-12 months (119). These results suggest that GnRH
Table II. Overview of trials using GnRH analogs in ovarian cancer.

| Drug               | Condition                  | Intervention                        | Histology (no. of samples)                                                                 | CR | PR | SD | Phase | (Refs.) |
|--------------------|----------------------------|-------------------------------------|------------------------------------------------------------------------------------------|----|----|----|-------|---------|
| Triptorelin        | Advanced EOC               | Long-acting depot/month             | 41; Serous, 28; endometrioid, 7; Mucinous, 1; Clear cell, 2; Mixed, 3                   | 0  | 6  | 5  | II    | (102)   |
| Triptorelin        | Advanced EOC               | 0.1 mg/daily or 3.2 mg/month depot  | 19; Serous: 19                                                                          | 0  | 11 | 0  | II    | (103)   |
| Triptorelin        | Progressive ovarian cancer | 3.75 mg for 4 weeks                 | 15; Serous, 12; Mucinous, 2; Brenner, 1                                                  | 0  | 0  | 14 | II    | (104)   |
| Triptorelin        | Relapsed ovarian cancer    | 3.2 mg for 4 weeks                  | 14; Serous, 8; Endometrioid, 3; Mucinous, 1; Anaplastic, 1; Mixed, 1                   | 0  | 0  | 8  | II    | (105)   |
| Triptorelin        | Relapsed EOC               | 3.75 mg/on days 1, 8 and 28 followed by 4-weekly | 69; Serous, 19; Endometrioid, 5; Mucinous, 4; Clear cell, 2; Mixed, 1; Undifferentiated, 5; Papillary, 6; Unspecified, 27; | 0  | 0  | 11 | II    | (106)   |
| Triptorelin        | Advanced EOC               | 3.75 mg/month depot                 | 69; Serous, 59; Endometrioid, 2; Mucinous, 4; Clear cell, 1; Undifferentiated, 3        | 0  | 0  | 0  | II    | (107)   |
| Triptorelin and tamoxifen | Progressive ovarian cancer | -                                   | 40; Serous, 15; Endometrioid, 2; Mucinous, 1; Solid, 4; Clear cell, 1                   | 0  | 0  | 1  | -     | (108)   |
| Goserelin          | Refractory EOC             | 3.6 mg/month                        | 23; Serous, 15; Endometrioid, 2; Mucinous, 1; Solid, 4; Clear cell, 1                   | 0  | 4  | 7  | II    | (109)   |
| Goserelin          | Relapsed EOC               | 3.6 mg/month                        | 30; Serous, 14; Endometrioid, 1; Mucinous, 4; Clear cell, 1; Mixed, 1; Undifferentiated, 7; Borderline, 2 | 0  | 2  | 5  | II    | (110)   |
| Goserelin and tamoxifen | Recurrent EOC             | Goserelin, 3.6 mg once a month; Tamoxifen, 40 mg/daily | 26; Serous, 14; Endometrioid, 1; Mucinous, 4; Clear cell, 1; Mixed, 1; Undifferentiated, 7; Borderline, 2 | 1  | 2  | 10 | II    | (111)   |
antagonists may be considered for the palliative treatment of patients with platinum-resistant OC.

4. Androgens

Androgens and their receptors in OC. The biological effects of androgens [testosterone and dihydrotestosterone (DHT), as well as certain androgens produced by the adrenal glands and ovaries] are typically mediated via the androgen receptor (AR), a steroid hormone receptor that is a member of the nuclear receptor superfamily (125-127). Under basal conditions, AR exhibits inactivity and can bind towards heat shock proteins and certain cellular partners. When activated by androgens, it induces a cascade of events (e.g., ligand binding, dissociation from heat shock protein, phosphorylation and dimerization) and is involved in nuclear translocation. Specific to the nucleus, AR binds to specific DNA sequences known as androgen response elements in the nucleus and binds to various AR cofactors to form complexes. The AR complex does not only alter the expression of genes involved in multiple physiological and pathological functions; however, under certain pathological conditions, AR may also become activated in the absence of androgens. For example, the activation of AR by IL-6 in human prostate carcinoma cells does not

| Drug          | Condition                          | Intervention                                      | Histology (no. of samples) | CR | PR | SD | Phase (Refs.) |
|---------------|------------------------------------|--------------------------------------------------|----------------------------|----|----|----|--------------|
| Leuprolide    | Relapsed EOC                       | 3.75 mg intramuscularly once a month              | 32                         | 0  | 4  | 5  | - (112)      |
| acetate       | Platinum-refractory ovarian cancer | 3.75 mg intramuscularly once a month              | 32; Serous, 25; Endometrioid, 4; Mucinous, 2; Unspecified, 1 | 1  | 2  | 4  | II (113)     |
| Leuprolide    | Platinum- and paclitaxel-refractory ovarian cancer | 3.75 mg intramuscularly every 4 weeks | 37; Serous, 19; Endometrioid, 6; Mucinous, 11; Unspecified, 1 | 0  | 0  | 4  | - (114)      |
| acetate       | Advanced EOC                       | 3.75 mg on days 1, 8, 28 followed by 28-day intervals | 12; Serous, 9; Endometrioid, 1; Mucinous, 2 | 0  | 1  | 3  | II (115)     |
| Leuprolide    | Refractory or persistent EOC       | 1 mg dose for a minimum of 8 weeks                | 18; Serous, 9; Endometrioid, 2; Mucinous, 3; Unspecified, 4 | 0  | 4  | 2  | II (116)     |
| acetate       | Advanced or recurrent ovarian cancer | 1 mg subcutaneously, daily                        | 5; Serous, 2; Mucinous, 1; Papillary, 1; Brenner, 1 | 1  | 4  | 0  | II (117)     |
| Leuprolide    | Advanced or recurrent EOC          | 1 mg subcutaneously daily                          | 25; Serous, 19; Endometrioid, 2; Mucinous, 1; Clear cell, 1; Mixed, 2 | 0  | 1  | 15 | II (118)     |
| acetate       | Platinum-resistant ovarian cancer   | 10 mg subcutaneously daily                         | 17; Serous, 10; Endometrioid, 5; Mixed, 2 | 0  | 3  | 6  | II (119)     |

EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; SD, stable disease.
require the presence of androgens (128). Androgen/AR signals have been reported to promote metastasis and tumorigenesis in various malignancies, including prostate carcinoma, for which androgen deprivation therapy remains the primary treatment option (129), but also in other types of cancer, such as breast (130) and bladder cancer (131).

In addition, there is accumulating evidence to indicate that AR and related signaling pathways are involved in the development and progression of OC. The expression of AR in OC was first demonstrated by Hamilton et al (132) with the use of ligand binding tests. According to in-depth research, AR expression has been detected in ~90% of EOCs using biochemical receptor tests (133) and in 43.5–86% of EOCs using immunohistochemistry (134,135). Some investigators have attempted to determine whether AR is differentially expressed in various histological subtypes of OC. According to Cardillo et al (136) the expression of AR varies widely across various histological subtypes of OC. The aforementioned result was verified by Elattar et al (137), who reported that AR was expressed in 43.7% of EOC samples, with the highest expression levels observed in serous carcinomas (47.5%). Similarly, according to de Toledo et al (138), AR-positive expression tended to exhibit a higher prevalence in serous tumors compared with that in non-serous tumors. The association between AR expression and other clinicopathological characteristics of OC, such as tumor stage and grade, was also assessed. According to Jönsson et al (139), a negative AR expression was associated with high-grade cancer. By contrast, four other studies on malignant ovarian tumors reported that AR expression exhibited no association with tumor FIGO stage (135,136,138,140). Furthermore, according to a previous study, matched primary and metastatic serous EOC samples exhibited non-significant differences in the levels of nuclear AR (140). In summary, AR expression is more frequently detected in serous compared with non-serous ovarian tumors; however, whether AR expression levels are crucial for OC progression requires further in-depth investigation.

Androgen-mediated AR signaling in ovarian tumorigenesis. Currently, a number of factors are known to be involved in regulating the transcriptional activity of AR, including not only various androgenic and androgen-derived compounds, but also the expression levels and variants of AR per se. Edmondson et al (141) first demonstrated that OSE cells were androgen-responsive, and the addition of androgen to eight primary human OSE cell lines cultured in vitro was able to promote the proliferation of these cells and reduce cell apoptosis. In other in vitro experiments, DHT and testosterone were shown to notably stimulate the proliferation of ovarian tumor and normal ovarian cell lines/cultures (142). Co-treating these cells with the anti-androgen 4-hydroxyflutamide also demonstrated that this androgen-stimulating effect was reversible (142). In another study, DHT stimulation was reported to increase cell division in six of 11 primary cultured EOC cell lines. The proportion of cells in the S phase also increased from 4.4% in serum-free medium to 8.3% in 100 nM DHT-stimulated cells (137). In that study, it was also found that AR nuclear expression was positively associated with an increased fraction in the S phase in response to androgen stimulation, while the expression of AR in the immunohistochemical nuclear and cytoplasm was significantly decreased following chemotherapy (137). This may explain the low response rates observed in clinical trials among patients who have received aggressive prior chemotherapy. Other androgens, such as androstenedione (143) and methylsone (144), have also been shown to increase the proliferation and induce cell motility and invasion in EOC lines. Animal models have also been used to evaluate the effect of androgens on EOC progression. According to Silva et al (145), testosterone therapy in guinea pigs promoted ovarian epithelial cell proliferation, leading to the formation of papillomas on the ovarian surface, small adenomas in the ovarian parenchyma and benign cysts. Similarly, in a mouse xenotransplantation model, DHT treatment significantly induced tumor growth (146), and the AR inhibitor enzalutamide was shown to antagonize the effects of DHT (147). These observations in animal models and cell lines suggest that androgen/AR signaling can critically stimulate EOC growth and promote EOC progression. The activation of AR signaling is likely to be associated with the sensitivity of malignant tumors to conventional chemotherapeutic agents, as suggested by research on prostate cancer (148) and bladder urothelial carcinoma (125). AR expression has also been found to be considerably upregulated in the paclitaxel-resistant SKOV3 subline (149). Correspondingly, as previously demonstrated, in paclitaxel-resistant SKOV3 cells, the silencing of AR via RNA interference increased cell sensitivity to chemotherapy and enhanced paclitaxel-mediated apoptosis (149,150). Conversely, the activation of AR with the agonist DHT has been shown to upregulate the expression of paclitaxel resistance target genes (150).

Clinical use of androgen deprivation therapy in patients with OC. As aforementioned, preclinical evidence suggests that androgen/AR signaling is associated with the progression of OC, and targeting AR is a promising treatment strategy. However, to date, only a small number of clinical trials have been conducted to evaluate the efficacy of anti-androgen therapy in OC, with or without GnRH agonists (Table III) (151-155). Notably, androgen deprivation therapy (e.g., bicalutamide and flutamide), with or without GnRH agonists, is extensively applied in patients with prostate cancer without severe side-effects, and functions by inhibiting pituitary LH release and ultimately reducing androgen production (49,156). In a previous study, Tumolo et al (151) assessed the use of flutamide, a non-steroidal AR antagonist, in patients with EOC who relapsed and progressed following platinum-based chemotherapy. First, 68 eligible patients were included, 32 of whom had completed oral flutamide therapy (750 mg/day) for at least 2 months. Of the 32 patients in the study, only 2 responded to the treatment and the disease was stable over a mean period of 24 weeks in 9 patients. Based on the results of that trial, it was concluded that flutamide was ineffective as a treatment for patients who had previously received extensive chemotherapy, and that it is associated with certain side-effects, such as nausea and vomiting. In another phase II study, Vassilomanolakis et al (152) assessed the response of patients with stage III or IV EOC to flutamide (300 mg/day) following chemotherapy. The outcome of that clinical trial was not satisfactory, with only 1 (4.3%) of the 23 evaluated patients exhibiting a partial response and 2 patients (8.7%) having
with the remaining 20 patients experiencing disease progression within 3 months. In addition, bicalutamide, a non-steroidal drug exhibiting anti-androgen characteristics, was tested in patients with grade II or higher EOC in remission (154). However, the results of that study demonstrated that the oral bicalutamide administration (30 mg/day) combined with subcutaneous goserelin injection (3.6 mg every 4 weeks) did not prolong progression-free survival (PFS) in 35 patients. In another later study, Gruessner et al. (153) investigated the effects of preoperative oral flutamide therapy (125 mg/day for 6 weeks) on biomarker levels in blood and tissue samples from 12 patients at a high risk of developing OC and 47 controls, 47% of whom had BRCA mutations. The results demonstrated that flutamide significantly reduced the expression of colony stimulating factor (CSF)-1 and Erb-B2 receptor tyrosine kinase 4 (ERBB4) in the ovarian stroma and was well-tolerated by the patients. Enzalutamide is an oral AR signaling inhibitor capable of blocking the binding of androgens to AR and preventing AR nuclear translocation, DNA binding and coactivator recruitment (157). In 2012, enzalutamide was approved by the US Food and Drug Administration for the treatment of castration-resistant prostate carcinoma. A phase II study is currently underway to evaluate enzalutamide in women with AR-positive OC (NCT 01974765) (155).

Evidence from limited clinical trials indicates that only a small proportion of patients with EOC benefit from androgen deprivation therapy consisting of non-steroidal anti-androgen drugs with generally tolerable side-effects. Therefore, further research is required to determine the actual benefit of androgen deprivation therapy and the optimal regimen, and to select appropriate drug candidates by evaluating AR expression, AR polymorphism/fragment variation and downstream targets of AR activity.

5. Estrogen

_Estrogen and ER in OC_. Estrogens belong to the family of steroid organic compounds and are mainly synthesized from androgens through the aromatase activity of granulosa cells in the ovaries. In fact, the term ‘estrogen’ refers to a group of female hormones, the most common of which are estrone, estradiol and estriol. Serum estrogen concentrations increase from the metaphase, consistent with the formation of dominant follicles. In the follicular fluid chambers, estrogen levels are 1,000-fold higher compared with those in peripheral blood. All these estrogens can bind to nuclear and membrane ERs with varying affinities and response strengths (158). Estrogen signal transduction is mediated by several estrogen isomers, the most important of which are the classical ERs, namely ERα and ERβ. Estrogen, as a steroid hormone, can cross the plasma membrane and interact with ERα and ERβ in the cells, acting directly by binding to DNA sequences. ER complexes bind directly or indirectly to DNA; thus, estrogen-mediated signaling events can be genomic as well as non-genomic. Genomic effects involve the migration of ER complexes to the nucleus and direct interaction with chromatin on specific DNA sequences, known as estrogen response elements (158,159). On the other hand, non-genomic effects involve the indirect regulation of gene expression through a variety of intracellular signaling

---

| Drug            | Condition                  | Intervention                        | Histology (no. of samples) | CR | PR | SD  | Phase | (Refs.) |
|-----------------|----------------------------|-------------------------------------|-----------------------------|----|----|-----|-------|--------|
| Flutamide       | Relapsed EOC              | 750 mg daily for at least 2 months  | 62; Serous, 33; Endometrioid, 1; Mucinous, 4; Clear cell, 1; Undifferentiated, 1; Unspecified, 22 | 1  | 1  | 9   | II    | (151)  |
| Flutamide       | Advanced EOC              | 100 mg three times daily            | 23; Serous, 17; Endometrioid, 2; Clear cell, 1; Mixed, 3 | 0  | 1  | 2   | II    | (152)  |
| Flutamide       | Pre-operative treatment EOC| 125 mg daily for 6 weeks           | 12                          | -  | -  | -   | II    | (153)  |
| Bicalutamide +  | Consolidation EOC         | Bicalutamide, 50 mg daily; goserelin, 3.6 mg every 4 weeks | 35; Serous, 30; Endometrioid, 3; Clear cell, 2 | -  | -  | -   | II    | (154)  |
| Enzalutamide    | Androgen receptor-positive EOC | 160 mg daily                        | 58                          | -  | -  | -   | II    | (155)  |

EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; SD, stable disease.
events. The G-protein coupled receptor (GPR)30, also known as G-protein coupled ER1, has been extensively investigated as a membrane ER that activates non-genomic estrogen signaling pathways in a variety of tissues (160).

ER\(\alpha\) is closely associated with endocrine sensitivity in breast cancer and is a significant mediator of the estrogen response in OC (161,162). Multiple studies have investigated the expression of ER\(\alpha\) in EOC (163-166); however, the largest study was conducted by the Ovarian Tumor Tissue Analysis consortium in 2013 (25). That study investigated 2,933 women and found that HGSC, LGSC and endometrioid OC exhibited the highest levels of ER positivity at 81, 88 and 77%, respectively; furthermore, these tumor types have exhibited responses to endocrine therapy (tamoxifen and aromatase inhibitors) in multiple clinical studies. By contrast, ER\(\alpha\) expression was detected in only 20 and 21% of clear cells in mucinous and clear cell carcinomas, respectively. ER\(\beta\) is known to be expressed as five different isoforms, namely ER\(\beta\)1‑5; however, only the full-length form of ER\(\beta\)1 is able to bind to agonist or antagonist ligands and has a more complex function (167). Rutherford et al (168) found higher levels of ER\(\beta\) expression in normal OSE cells, lower levels of ER\(\beta\) expression in primary EOC, and the absence of ER\(\beta\) expression in metastatic tumors. These results indicate that there may be fundamental differences in ER\(\beta\) expression from the normal ovarian tissue to primary OC to metastatic tumor (168).

**Estrogen signaling in OC.** ER is highly expressed in several EOCs and is a potential target for endocrine therapy. Studies using in vitro experiments and in vivo animal models of EOC support the hypothesis that ER expression levels are a crucial determinant of the response to treatment with selective ER modulators. In addition, epidemiological studies have demonstrated that the long-term use of estrogen-only therapy increases the risk of developing OC in women, supporting the hypothesis that estrogen signaling contributes to the etiology of the disease.

In vitro cultured EOC cells exhibiting a high ER\(\alpha\) expression can be stimulated by estrogen, while treatment with selective ER modulators (tamoxifen and fulvestrant) can inhibit the growth of EOC cell xenografts with a high ER\(\alpha\) expression in vivo (161,163,169,170). By contrast, estrogen has been shown to exert no effect on ER\(\alpha\)-negative cell lines (170). The silencing of ER\(\alpha\) expression in SKOV3 EOC cells has been shown to inhibit estrogen-stimulated proliferation and reverse the inhibitory effects of 4-hydroxytamoxifen (an active metabolite of tamoxifen) and fulvestrant, indicating that the effects of these selective ER modulator were ER\(\alpha\)-mediated (171). In another study, the treatment of patient-derived xenografts (PDXs) from patients with ER\(\alpha\)-positive/ER\(\beta\)-negative HGSC with 4-hydroxytamoxifen or fulvestrant also provided support for the ER\(\alpha\)-mediated action of these drugs (165). Of the four PDXs, two xenografts with higher levels of ER\(\alpha\) expression exhibited reduced diffusion during drug therapy, while the two xenografts with lower levels of ER\(\alpha\) expression were not affected, meeting the requirements for a higher level of ER\(\alpha\) response. Fulvestrant decreased the protein expression of ER\(\alpha\) in the reaction cells, which was consistent with its action pattern (165). In addition to regulating proliferation, estrogen promotes cell migration and epithelial-to-mesenchymal transition through ER\(\alpha\), and these changes are mediated by the Snail- and Slug-mediated downregulation of E-cadherin (172). The extracellular molecule, fibulin, which binds to fibronectin and laminin, is also regulated by estrogen through ER\(\alpha\) and is considered to play a key role in cell attachment and motility (173).

The previous evaluation of the role of ER\(\beta\) suggested that this receptor isoform functions as a tumor suppressor in EOC by reducing tumor growth and deterring metastasis. These actions rely on the fact that ER\(\beta\) inhibits ER\(\alpha\) expression and decreases estradiol-induced cell proliferation (174,175). In addition, the restoration of ER\(\beta\) expression in EOC cells has been shown to lead to a decrease in proliferation and invasion, while apoptosis is enhanced (176). Similarly, the overexpression of ER\(\beta\)1 induced by transfection with an overexpression vector in the SKOV3 EOC cell line (177) or the ES-2 cell line (178) has been shown to result in reduced proliferation and motility, and increased apoptosis. The gene ER\(\beta\), is localized on chromosome 14q, and this region is frequently deleted in OC (176). Consistent with its tumor-suppressive effect, the high expression of ER\(\beta\)1 in the cytoplasm of EOC cells has been found to be strongly associated with a longer disease-free and overall survival of patients (179). In contrast to the inhibitory role of ER\(\beta\)1, both ER\(\beta\)2 and ER\(\beta\)5 have been associated with pro-migratory and invasive activities. ER\(\beta\)2 overexpression has been shown to increase cell migration and invasion, but not the proliferation of EOC cells (179). The mitochondrial activity of cytoplasmic ER\(\beta\)2 signaling in serous carcinomas has been found to be associated with BAD binding, leading to reduced apoptosis, thereby serving a pro-survival role (174). ER\(\beta\)5 also plays an important role in tumor progression and has been shown to promote cell proliferation, and enhance cell migration and invasion. High levels of ER\(\beta\)5 expression have been found in the nuclei of tumor cells from patients with clinically advanced EOC (particularly serous and clear cell carcinomas), which has also been associated with poor patient survival, although some researchers have reported that cytoplasmic ER\(\beta\)5 expression may be associated with more favorable patient outcomes (179). The cell cycle is affected by the presence of ER\(\beta\) by reducing the proportion of cells in the S phase, increasing the number of cells in the G1/M phase, and inducing apoptosis (167,175). A suppressive effect of ER\(\beta\) on cyclin D1 expression has been reported, and its expression appears to be enhanced in response to estrogen antagonists (180). Indirect evidence that ER\(\beta\) is implicated in ovarian carcinogenesis is the fact that its expression has been found to be significantly associated with survival in human and animal models (181,182). A recent study revealed that ER\(\beta\)-positive nuclear staining was associated with a decreased PFS (183). On the other hand, patients with hormone receptor-negative OC have been shown to have a favorable prognosis (184).

**Targeting ER with selective ER modulators and aromatase inhibitors in OC.** Several clinical trials have been conducted using selective ER modulators (mainly tamoxifen) and aromatase inhibitors (letrozole and anastrozole), which have exhibited activity against OC (low response rate, yet apparently SD) and these are discussed below (Tables IV and V) (108,185-213).
Table IV. Overview of trials using tamoxifen in ovarian cancer.

| Drug             | Condition                  | Intervention  | Histology (no. of samples) | CR | PR | SD | Phase  | (Refs.) |
|------------------|----------------------------|---------------|----------------------------|----|----|----|--------|---------|
| Tamoxifen        | Advanced EOC              | 40 mg daily   | 6                          | 0  | 1  | 1  | II     | (185)   |
|                  |                            |               | Serous, 3; Endometrioid, 1; Mucinous, 1; Clear cell, 1 |    |    |    |        |         |
| Tamoxifen        | Recurrent EOC             | 40 mg daily   | 47-                        | 1  | 2  | 22 | -      | (186)   |
| Tamoxifen        | Recurrent ovarian cancer  | 30 or 40 mg daily | 65; Endometrioid, 10 Non-endometrioid, 55 | 2  | 2  | 50 | -      | (187)   |
| Tamoxifen        | Advanced EOC              | 40 mg daily   | 30; Serous, 25; Endometrioid, 1; Mucinous, 1; Clear cell, 2; Adenosquamous, 1 | 2  | 0  | 10 | II     | (188)   |
| Tamoxifen        | Progressive ovarian cancer| 30 mg daily   | 33-                        | 0  | 0  | 2  | II     | (108)   |
| Tamoxifen        | Refractory EOC            | 80 then 40 mg daily | 29; Serous, 5; Endometrioid, 2; Mucinous, 1; Clear cell, 1; Papillary, 17; Undifferentiated, 3 | 2  | 3  | 18 | II     | (189)   |
| Tamoxifen        | Recurrent EOC             | 30 mg daily   | 26; Serous, 10; Endometrioid, 4; Mucinous, 5; Clear cell, 3; Undifferentiated, 4 | 0  | 0  | 7  | II     | (190)   |
| Tamoxifen        | Recurrent EOC             | 20 mg daily   | 21                         | 1  | 7  | 12 | II     | (191)   |
| Tamoxifen        | Refractory ovarian cancer | 100 then 40 mg daily | 51                        | 0  | 1  | 0  | II     | (192)   |
| Tamoxifen        | Relapsed EOC              | 40 mg daily   | 22                         | 0  | 0  | 1  | II     | (193)   |
| Tamoxifen        | Recurrent EOC             | 20-40 mg daily | 23                        | 0  | 0  | 19 | II     | (194)   |
| Tamoxifen        | Advanced ovarian cancer   | 40 mg daily   | 105; Serous, 57; Endometrioid, 15; Mucinous, 6; Clear cell, 4; Mixed, 8; Adenosquamous, 1; Unspecified, 12; Undifferentiated, 2 | 10 | 8  | 40 | II     | (195)   |
| Tamoxifen        | Recurrent EOC             | 20 mg daily   | 29; Serous, 22; Endometrioid, 3; Mucinous, 1; Mixed, 1; Undifferentiated, 2 | 1  | 2  | 6  | II     | (196)   |
Tamoxifen was the first selective ER modulator to be evaluated in clinical trials for OC and is still in use today; it is considered to function as a selective ER modulator that competes with estrogen for binding to the ERα and, thus, functions as an ER antagonist. The majority of studies were designed as single-arm studies to assess whether tamoxifen can induce a response in EOC; however, they did not evaluate the effects of tamoxifen on symptom control, the quality of life or the survival time of patients. It has been reported that the overall mean response rate of this treatment is 10-15%, and the disease stability rate is 30-40% (214-216). In clinical trials in which tamoxifen was applied, the majority of patients had undergone major pre-treatment procedures, such as chemotherapy, and several studies did not differentiate between ER-positive patients. Perez-Gracia and Carrasco (215) reported an overall response rate of 26% and a complete response rate of 9% in the analysis of trials using tamoxifen in at least 50% of cases not having received multiple prior treatments, compared with a clinical study treating patients with severe disease with an effectiveness rate of only 4% (215). For 19 years, non-steroidal aromatase inhibitors have been studied for their antitumor activity, which appears to be comparable to that of tamoxifen, by inhibiting the conversion of androgens to estrogens, thereby reducing circulating estrogen levels. Paleari et al (216) reviewed 53 endocrine therapy trials including a total of 2,490 patients in their meta-analysis. The clinical benefit rate (CBR; percentage of total patients exhibiting complete response, partial response or SD in all endocrine therapy evaluations) reached 41%; the CBR for tamoxifen was 43% (23 trials) and the CBR for aromatase inhibitors was 39% (10 trials), demonstrating that the effectiveness of the two types of drugs was comparable for patients with advanced EOC (216). According to a recently conducted trial (PARAGON), the application of anastrozole in a phase II study on asymptomatic cases suffering from ER- and PR-positive recurrent EOC with CA125 progression was assessed (217). The response rate reached 4%, and the CBR reached 35%, which was disappointing, given that these cases only had limited disease and had previously received single chemotherapy treatment.

Table IV. Continued.

| Drug                     | Condition                          | Intervention                                      | Histology (no. of samples) | CR | PR | SD | Phase | (Refs.) |
|--------------------------|------------------------------------|--------------------------------------------------|----------------------------|----|----|----|-------|---------|
| Tamoxifen                | Advanced ovarian cancer            | 20 mg daily                                      | 13                         | 0  | 1  | 4  | -     | (197)   |
| Tamoxifen                | Relapsed EOC                       | 20 or 40 mg daily                                | 43;                       | 0  | 6  | 22 | -     | (198)   |
|                          |                                    |                                                  | Serous, 22;               |    |    |    |       |         |
|                          |                                    |                                                  | Endometrioid, 13;        |    |    |    |       |         |
|                          |                                    |                                                  | Clear cell, 6;           |    |    |    |       |         |
|                          |                                    |                                                  | Undifferentiated, 2      |    |    |    |       |         |
| Tamoxifen                | Recurrent EOC                      | 40 mg daily                                      | 68;                       | 0  | 0  | 5  | III   | (199)   |
|                          |                                    |                                                  | Serous, 56               |    |    |    |       |         |
|                          |                                    |                                                  | Endometrioid, 2;         |    |    |    |       |         |
|                          |                                    |                                                  | Mixed, 7;                |    |    |    |       |         |
|                          |                                    |                                                  | Unspecified, 3           |    |    |    |       |         |
| Tamoxifen and cytotoxic  | Advanced EOC                       | Tamoxifen, 10 mg twice daily;                    | 49;                       | 0  | 0  | 0  | II    | (200)   |
| chemotherapy             |                                    | cis-diaminedichloroplatinum (50 mg/m²) and       |                            |    |    |    |       |         |
|                          |                                    | doxorubicin (50 mg/m² every 4 weeks              |                            |    |    |    |       |         |
| Tamoxifen and platinum   | Recurrent or progressive EOC       | Tamoxifen, 80 mg daily for 1 month then 40 mg    | 50;                       | 15 | 10 | 12 | II    | (201)   |
| (P)-based chemotherapy   |                                    | daily; cisplatin, 100 mg/m² or carboplatin,     |                            |    |    |    |       |         |
|                          |                                    | 400 mg/m², every 21 days                         |                            |    |    |    |       |         |
| Tamoxifen and carboplatin| Platinum-resistant EOC             | Tamoxifen: 80 mg daily for 1 month then 40 mg    | 14                         | 0  | 0  | 0  | II    | (202)   |
|                          |                                    | daily; carboplatin: every 21 days                |                            |    |    |    |       |         |
| Tamoxifen and gefitinib  | Refractory or resistant EOC        | Tamoxifen: 40 mg daily; gefitinib: 500-250 mg    | 56-                       | 0  | 0  | 16 | II    | (203)   |

EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; SD, stable disease.
Two recent reports described studies evaluating the use of endocrine therapy at their respective centers and provided insight into settings outside of HGSOC trials. An analysis of 97 patients treated at the Royal Marsden Hospital (London, UK) investigated the use of tamoxifen and letrozole for advanced EOC (91% HGSOC) (198). More than a quarter of the patients had previously received five or more types of chemotherapy, and half of these had an unknown ER status, whereas the CBR reached 60% (tamoxifen, 65%; and letrozole, 56%). Cases responding to letrozole had a significantly longer response time (198). A 25-year analysis of 269 cases with HGSOC in Edinburgh revealed a comparable overall response rate for letrozole and tamoxifen (8% and 11%, respectively) and CBR (41% and 33%, respectively). Cases with a high ER expression and a longer treatment-free interval were most likely to benefit from these treatments (218). The

| Drug                  | Condition                        | Intervention | Histology (no. of samples) | CR | PR | SD | Phase (Refs.) |
|-----------------------|----------------------------------|--------------|----------------------------|----|----|----|---------------|
| Letrozole             | Relapsed EOC                     | 2.5 mg daily | 60; Serous, 43; Endometrioid, 11; Undifferentiated, 6 | 0 | 5 | 14 | II (204) |
| Letrozole             | Relapsed or recurrent EOC        | 2.5 mg daily | 27; Serous, 15; Endometrioid, 2; Clear cell, 1; Unspecified, 9 | 1 | 3 | 5 | II (205) |
| Letrozole             | Estrogen receptor-positive ovarian cancer | 2.5 mg daily | 44; Serous, 23; Endometrioid, 4; Mixed, 17 | 0 | 7 | 11 | II (206) |
| Letrozole             | Recurrent and advanced EOC       | 2.5 mg daily | 13 | 2 | 2 | 5 | - (207) |
| Letrozole             | Recurrent platinum- and taxane-resistant ovarian cancer | 2.5 mg daily | 33; Serous, 29; Mixed, 3; Adenocarcinoma, 1 | 0 | 1 | 7 | II (208) |
| Letrozole             | Estrogen receptor-positive ovarian cancer | 2.5 mg daily | 14 | 5 | 0 | 5 | - (209) |
| Letrozole             | Relapsed EOC                     | 2.5 mg daily | 54; Serous, 25; Endometrioid, 15; Clear cell, 10; Unspecified, 4 | 0 | 8 | 22 | - (198) |
| Letrozole + everolimus| Relapsed estrogen receptor-positive ovarian cancer | Letrozole: 2.5 mg daily; Everolimus: 10 mg daily | 19; Serous, 17; Carcinosarcoma, 1; Transitional cell carcinoma, 1 | 0 | 0 | 9 | II (210) |
| Anastrazole           | Recurrent/persistent ovarian cancer | 1 mg daily | 53; Serous, 38; Endometrioid, 3; Clear cell, 1; Unspecified, 11 | 0 | 1 | 22 | II (211) |
| Anastrazole + gefitinib| Recurrent EOC                   | Anastrazole, 1 mg daily; Gefitinib, 250 mg daily | 23 | 1 | 0 | 14 | II (212) |
| Exemestane            | Refractory ovarian cancer        | 25 mg daily | 22 | 0 | 0 | 8 | II (213) |

EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; SD, stable disease.
conclusions of these two analyses are consistent with the findings of clinical trials, demonstrating that tamoxifen or letrozole constitute reasonable treatment options for patients with ER-positive HGSOC, with a comparable overall response rate, CBR and disease stability. Endocrine therapy may be a promising alternative therapy for LGSOC, which is less sensitive to chemotherapy. Gershenson et al (219) identified a 9% response rate and 61% disease stabilization rate in a retrospective analysis of 64 LGSOC cases who had received a total of 89 hormonal regimens. The PFS for cases receiving hormonal maintenance therapy (primarily letrozole or tamoxifen) was 65 months, compared with 26 months for cases under observation only (P<0.001) (219). That study was followed-up by Fader et al (220), who also retrospectively explored the use of adjuvant hormonal therapy following surgery without chemotherapy, with promising results. A stage III trial initiated in 2019 (NRG-GY019) is also currently ongoing. Specifically, the comparison is between paclitaxel/carboplatin + letrozole vs. letrozole independently for stage II-IV LGSOC (221). To date, there is limited information available on the sensitivity of endometrioid OC to hormone therapy. In the Royal Marsden High Grade Ovarian Cancer Study, a total of 5 patients with high-grade endometrioid OC were treated with endocrine therapy and, encouragingly, 3 patients exhibited partial remission, while the remaining 2 patients had SD (198). In a study on letrozole reported by Bowman et al (204), 4/11 endometrioid OC cases had SD compared with 4/43 serous carcinoma cases. Moreover, estrogen-targeting therapies have exhibited considerable promise in the treatment of GCTs. In a review article summarizing aromatase inhibitors as single agents, 25 cases with known outcomes were described. The response rate to aromatase inhibitors in these patients was 48% (12/25) and the clinical benefit rate was 76% (19/25) (222). According to a previous analysis, 9 out of 9 patients responded to aromatase inhibitors. Although the number of patients in those studies was limited, they supported aromatase inhibitors as a potential alternative to chemotherapy (223).

6. Progesterone and progestins

**Progesterone (P4) and PR in OC.** Progesterone (P4) is a steroid hormone mainly generated from the corpus luteum in the ovaries during the luteal phase or the second half of the menstrual cycle. The adrenal glands and the placenta during pregnancy also produce small amounts of progesterone (224,225). Thus, from the beginning of menstruation to the end of menopause, there is a monthly cycle of hormone exposure, and the regulation of the growth and differentiation of the female reproductive tract system and breast tissue (225). Pregnancy interrupts this cyclic process, as high progesterone levels are continuously required for fetal growth, the maintenance of uterine/placental integrity and breast development during lactation (226). Progesterone-dependent effects and related biological actions in different tissues and tumors are mediated by two PR subtypes, namely PR-A and PR-B. PR-B is the major subtype required for mammary gland development and expansion, while PR-A is required for normal uterine development and reproductive activity (227). PR is a polypeptide expressed in the cytoplasm, and once bound to progesterone, it translates into the nucleus and regulates the expression of a specific set of genes. Limited studies have reported information on the relative expression of PR in tissue samples from human OC subtypes. Diep et al (228) assessed the percentage of PR-positive tumors among primary histological subtypes of OSE-derived OC in 504 tissue samples. According to their results, 35% of ovarian tumors were PR-positive, with the maximal total PR expression found in the endometrioid (67%) and serous (35%; LGSOC, 64%) subtypes (228). Subsequently, the International Consortium for Ovarian Tissue Analysis analyzed the proportion of tumors positive for PR staining in ~3,000 invasive epithelial ovarian tumors and reported the highest expression in endometrioid (67.4%) and LGSOC (57.4%); intermediate expression in HGSO (31.1%); and the lowest expression in the mucinous (16.4%) and clear cell subtypes (8.0%) (25). Additionally, that study investigated the prognostic implications of PR expression in ovarian tumors highly expressing PR (staining of 50% tumor cell nuclei). PR expression was associated with a significantly favorable survival for HGSO, and significantly improved disease-specific survival independent of patient age, tumor grade, site and stage for endometrioid OC (25).

To the best of our knowledge, only three studies to date have reported the differential expression of PR isoforms in ovarian tumors (229-231). These studies reported the dominance of PR-B expression in all subtypes of ovarian tumors; furthermore, PR-B is usually expressed in serous subtypes, whereas PR-A is weakly expressed in mucinous and serous OC, and its expression is low or absent in tumors compared with that of PR-B in comparison with normal and malignant ovarian tissues.

**Progesterone signaling actions in OC.** The first indication that progesterone may be involved in the regulation of OC is derived from the observation that the use of progestin-containing oral contraceptives appears to prevent the occurrence of OC (232). Moreover, the incidence of OC is increased among women with progesterone deficiency, while the high levels of serum progesterone during pregnancy are associated with a lower risk of developing OC (233,234). The protective effect of progesterone against OC development is lost in post-menopausal women, as the serum levels of progesterone are negligible following menopause (235). In addition, women with a history of twin pregnancies exhibit a lower risk of developing OC, which may be associated with the higher serum levels of progesterone in the maternal circulation in twin compared with singleton pregnancies (236,237). The molecular mechanisms through which progesterone exerts its protective effects against OC are not yet well understood. Both proliferative and inhibitory effects of progesterone on OC cells have been reported in cell line assays, which may be attributed, at least in part, to the differential effects of progesterone on the two receptors, PR-A and PR-B, and their relative expression in target cells. Several independent in vitro studies have demonstrated the anti-proliferative effects of progesterone at higher concentrations in EOC cells, primarily through the induction of apoptosis (238-240). The activation of progesterone signaling can inhibit ovulation, antagonize the growth-promoting effects of estrogen, and regulate EOC cell proliferation and apoptosis (241). High concentrations of estrogen combined with progesterone may induce the apoptosis of EOC cells by promoting the expression
of let-7a and microRNA-34b, and decreasing the expression of Bcl-2 (241). In another study, however, it was demonstrated that the combination of tamoxifen and progesterone treatment induced apoptosis similar to that induced by treatment with progesterone independently, with no additional anticancer effect on EOC cells (242).

The precursor form of the steroid hormone progesterone reduces ovarian cell proliferation and viability by downregulating the expression of PR (243). Recently, Pedernera et al (244) observed that progesterone treatment significantly reduced cell survival in endometrioid OC. That study demonstrated the protective effects of progesterone against OC and indicated that the presence of PRs may suppress the progression of endometrioid OC. Of note, as demonstrated in a previous study, the progesterone metabolite, allopregnanolone, increased the proliferation of and Ki67 expression in EOC IGROV-1 cells, whereas the expression of cleaved caspase-3 was unaltered (239). Furthermore, progesterone and allopregnanolone increased the migratory capacity of IGROV-1 cells in a concentration-dependent manner (239). Moreover, it has been demonstrated that PR membrane component-1 (PGRMC1) plays an important role in promoting EOC cell viability by binding to progesterone, and that the attenuation of PGRMC1 function by small interfering RNA increases the sensitivity of EOC cells to cisplatin (237,245). The prolonged presence of the anti-progestin, mifepristone, has also been shown to block the repopulation of EOC cells that escaped platinum or platinum/paclitaxel treatment, providing evidence of the long-term use of anti-progestins as anti-repopulation therapy for cells that escape other effective chemotherapies (246-248). However, as progesterone/PR signaling is complex, further research on the intricate details of its role in tumor progression is required before it can be considered as a potential clinical target in OC treatment.

**Clinical trials of progesterone in recurrent OC.** Despite the high expression levels of endocrine response receptors, hormonal therapy plays merely a secondary role in EOC treatment. Epidemiological evidence coupled with the findings of in vivo and in vitro studies suggests the modulation of PR levels or activity as a form of endocrine therapy for EOC (Table VI) (189,249-262). In a phase II clinical trial conducted in 2000, 34 patients with recurrent EOC who no longer responded to cisplatin/paclitaxel chemotherapy were administered 200 mg oral mifepristone daily for 28 days. Of these patients, 9 responded to mifepristone, exhibiting a decrease in tumor size by at least 50% or a 50% decrease in the levels of CA125, which is used to assess disease recurrence (261). However, the results from another phase II clinical trial including 24 patients with advanced EOC who received standard chemotherapy and relapsed within 6 months, demonstrated that only 1 patient had an objective response to a 28-day regimen of 200 mg mifepristone administered daily (262). This clinical evidence appears to be less convincing in terms of the number of patients included, the lack of biomarkers to predict the response, and the fact that the studies did not report hormone receptor expression levels in OC tissue. Niwa et al (263) investigated the effects of the combination of medroxyprogesterone acetate (MPA) with primary adjuvant chemotherapy for advanced EOC in 2008. Both PFS and overall survival were significantly longer in the cases treated with the combination of MPA and platinum-based chemotherapy compared with those in the control group. Zheng et al (264) reviewed the value of PR ligands in OC treatment by examining 13 clinically related trials that included 432 cases with recurrent or refractory OC treated with megestrol acetate or MPA. A total of 10 cases (2.3%) had a complete response, 21 (4.9%) had a partial response and 47 (10.9%) had SD. The authors of that study concluded that the effectiveness achieved by progesterone preparations in recurrent EOC was not confirmed by existing research. In addition, the anti-progestin, mifepristone, is employed in the treatment of platinum-resistant EOC. PR can be induced by estrogen (and by tamoxifen, if serving as an agonist), and several trials have investigated the effectiveness achieved by combination hormonal therapy that targets the mentioned crosstalk (206,265,266). One noticeable clinically related response was observed in a trial of 65 patients with refractory EOC who were administered medroxyprogesterone and sequential ethinyl estradiol, achieving a response rate of 14% and SD in 20% of the patients (267). Given the recent preclinical data and basic research findings, it is expected that drugs targeting different PR subtypes (PR-A vs. PR-B), or drugs targeting other progesterone-binding receptors, will be developed and used in the near future.

### 7. Hormone replacement therapy and the risk of ovarian cancer

Findings by epidemiology researches on menopausal hormone replacement therapy (HRT) and the risk of developing OC are inconsistent. HRT exhibits an association with an increased risk of developing OC. Nevertheless, some researchers have reported that they found no such association, whereas other researchers have reported a positive association within the single histology subdivided type. As concluded from previous a review and meta-analysis of information (1966 and 2006), examining the application of post-menopausal hormone therapy (HT), an upregulated risk of developing OC by 30% was observed in contrast to no HT; it was thus indicated that the risk of developing OC with estrogen therapy (ET) was independently higher than that related to estrogen plus progestin therapy (EPT) (268). Nevertheless, the Million Women Study examined 2,273 incident cases of OC and with 948,576 females, reported an increased risk of developing OC by 30% was observed in contrast to no HT; it was thus indicated that the risk of developing OC with estrogen therapy (ET) was independently higher than that related to estrogen plus progestin therapy (EPT) (269); similarly, another nationwide study found no evidence of risk associated with vaginal ET or transdermal vs. oral EPT (270). Furthermore, in other studies, cyclic treating process were reported to increase the risk of OC, and no statistics-related significant differences were found from the cyclic combined regimen (28,271). A national prospective cohort study covering overall Danish females aged 50-79 years from 1995-2005 suggested an increased risk of developing OC with EPT and estrogen therapy, exhibiting an insignificant effect exerted by various doses, the length of use, routes of administration, progestin types and regimens (22). Based on the investigation of the identical cohort of cases recruited, as was reported, the risk of developing OC was altered in accordance with the histology
Table VI. Overview of trials using progestins (MA and MPA) and anti-progestins in persistent or recurrent EOC.

| Drug               | Condition                                | Intervention                                      | Histology (no. of samples)                                      | CR | PR | SD | Phase | (Refs.) |
|--------------------|------------------------------------------|---------------------------------------------------|---------------------------------------------------------------|----|----|----|-------|---------|
| Medroxyprogesterone| Advanced EOC                             | 800 mg daily                                      | Serous, 16; Endometrioid, 7; Mucinous, 1; Clear cell, 4; Undifferentiated, 2 | 0  | 0  | 2  | II    | (249)  |
| Medroxyprogesterone| Advanced EOC                             | 500 mg daily for 4 weeks, then 500 mg twice weekly for 4 weeks, then 500 mg once weekly | Serous, 20; Endometrioid, 8; Mucinous, 2; Undifferentiated, 3 | 0  | 5  | 2  | II    | (249)  |
| Medroxyprogesterone| Advanced EOC                             | 1,000 mg weekly by intramuscular injection        | -                                                             | 0  | 0  | 1  | II    | (250)  |
| Medroxyprogesterone| Advanced chemotherapy-resistant EOC       | -                                                 | -                                                             | 0  | 0  | 0  | II    | (251)  |
| Medroxyprogesterone| Advanced ovarian cancer                   | 500 mg daily                                      | -                                                             | 0  | 1  | 9  | II    | (252)  |
| Medroxyprogesterone| Advanced EOC                             | 500 mg daily, then 1,000 mg weekly                | Serous, 18; Endometrioid, 2; Mucinous, 3; Brenner, 3; Adenocarcinoma,12 Undifferentiated, 3 | 0  | 1  | 7  | II    | (253)  |
| Medroxyprogesterone| Advanced or recurrent EOC                 | 150 mg daily                                      | Serous, 17; Endometrioid, 4; Mucinous, 2; Undifferentiated, 1 | 0  | 1  | 9  | II    | (254)  |
| Megestrol acetate  | Ovarian adenocarcinoma                    | 800 mg daily for 4 weeks, then 400 mg daily daily | Adenocarcinoma, 23                                            | 7  | 4  | 0  | I-II  | (255)  |
| Megestrol acetate  | Resistant EOC                             | 800 mg daily for 4 weeks, then 400 mg daily daily | Serous, 37; Endometrioid, 6; Clear cell, 2                    | 1  | 3  | 5  | II    | (256)  |
| Megestrol acetate  | Progressive or recurrent EOC              | 160 mg daily                                      | Serous, 28; Endometrioid, 2; Clear cell, 1; Brenner, 1; Undifferentiated, 1 | 0  | 0  | 12 | II    | (257)  |
| Megestrol acetate  | Resistant ovarian cancer                  | 800 mg daily for 30 days, then 400 mg daily daily | Serous, 3; Endometrioid, 4; Mucinous, 1; Clear cell, 2; Papillary, 18; Undifferentiated, 4 | 0  | 0  | 13 | II    | (189)  |
of the tumor: In contrast to never users, females undergoing unopposed oral estrogen therapy exhibited an increased risk of developing ovarian serous and endometrial-like tumors, whereas they exhibited a decreased risk of developing mucinous tumors (272). According to a previous study analyzing the risk of developing OC in post-menopausal females treated with estradiol-progestin, the elevated risk of developing OC associated with EPT use over a period of 5 years was only observed in serous and mixed cancers, while the risk of mucinous cancers was reduced (270). A recently conducted meta-analysis reported by Liu et al (273) concluded that EPT during menopause may increase the risk of developing OC, particularly in terms of endometrioid and serous tumors. In a collaborative re-analysis of 52 epidemiological studies in the OC Epidemiology Research Collaborative (274), the relative risk (RR) of HRT for a duration of ≥5 years was more notable than that observed with past users who had terminated the therapy <5 years earlier. It was thus concluded that this increased risk was likely to be primarily or entirely involving a cause; if causal, female users who had been on hormone therapy for 5 years from the age of ~50 years would have one additional OC for every 1,000 users and, if their prognosis was characteristic, one additional OC-related death for every 1,700 users.

The effects of post-operative HRT on non-progression and total survival within cases of EOC is also controversial. The present review article can support the assumption that, i.e., HRT following surgery cannot adversely affect the non-progression and total survival of EOC cases. A retrospective study that included 77 cases supported the assumption that HRT following surgery failed to not significantly influence non-progression and total survival in cases suffering from EOC. Likewise, various HRTs (an estrogen-tibolone integration, tibolone independently, or estrogen independently) failed to notably affect the prognosis of patients with EOC (275). This finding was validated in another meta-analysis that covered 419 EOC survivors using HRT and 1,029 non-users (276). In a recent meta-analysis that included 350 cases suffering from EOC, the authors concluded that HRT may slightly improve the total survival of cases who had undergone surgical treatment, and there may be a minimal or no effect of HRT use on non-progression survival (24).

### Table VI. Continued.

| Drug              | Condition     | Intervention                                      | Histology (no. of samples)                                           | CR | PR | SD | Phase | (Refs.) |
|-------------------|---------------|--------------------------------------------------|---------------------------------------------------------------------|----|----|----|-------|---------|
| Megestrol acetate | Advanced ovarian cancer | 800 mg daily for 30 days, then 400 mg daily | Serous, 33; Endometrioid, 3; Mucinous, 2; Clear cell, 2; Adenocarcinoma, 23; Undifferentiated, 4 | 0  | 1  | 9  | II    | (258)  |
| Megestrol acetate | Resistant EOC | 200 mg four times daily | Serous, 9; Endometrioid, 4; Mucinous, 2; Adenocarcinoma, 11; Papillary, 4 | 0  | 0  | 0  | II    | (259)  |
| Megestrol acetate | Refractory EOC | 800 mg daily for 4 weeks, then 400 mg daily | Serous, 7; Endometrioid, 9; Mucinous, 8; Clear cell, 10; Adenocarcinoma, 2 | 3  | 4  | NA | II    | (260)  |
| Mifepristone      | Refractory EOC | 200 mg daily | Serous, 25; Endometrioid, 2; Clear cell, 1; Undifferentiated, 6 | 3  | 6  | NA | II    | (261)  |
| Mifepristone      | Recurrent or EOC Persistent | 200 mg daily | Serous, 19; Endometrioid, 1; Adenocarcinoma, 2 | 0  | 1  | 3  | II    | (262)  |

EOC, epithelial ovarian cancer; CR, complete response; PR, partial response; SD, stable disease.
8. Conclusions and future perspectives

In summary, OC is a malignancy depending on hormones in which steroid hormones and the relevant receptor critically affect its advancement. Although hormone therapy is effective in cases with advanced or recurrent OC, and has a low profile of toxicity, studies evaluating the therapeutic value of hormone therapy in OC have not been conclusive due to small sample sizes, different pathological types of OC, different hormone receptor-expressing states within OC cells, and the lack of molecular markers. In addition, the lack of corresponding NCT numbers for a number of clinical trials also does not facilitate the readers' understanding of the trials and may affect the authenticity of the trial results. Therefore, multicenter, prospective, randomized trial studies are required to confirm its efficacy. In addition, further studies are warranted to determine whether the combination of hormones and chemotherapeutic drugs can improve the effectiveness of chemotherapy, and whether this can be used as therapy for OC, as well as to identify the molecular markers of hormone therapy. In cases suffering from ER-positive breast carcinoma, hormone therapy has been used as part of systemic cancer treatment, and in endometrial cancer, hormone therapy functions as a second-line treatment option in terms of cancer metastasis. The ovary as an endocrine organ and the application of hormone therapy in OC patients, is worthy of further study. In future clinical treatment, hormone receptor expression should be routinely tested, and the expression should be standardized and classified into treatment considerations. In addition, different treatment options should be adopted according to the various pathological types of OC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Major Scientific and Technological Special Project for the 'Significant New Drugs Development' (grant no. 2018ZX09201018-013) and the National Natural Science Foundation of China (grant no. 81821002).

Availability of data and materials

Not applicable.

Authors' contributions

HL and YL wrote the initial manuscript and confirm the authenticity of all the raw data. YW created the figures and contributed to writing the material and providing new ideas. XZ and XQ revised the manuscript and approved the final version. All authors (HL, YL, YW, XZ, XQ) read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 68: 394-424, 2018.
3. Reid BM, Pernthuth J and Sellers TA: Epidemiology of ovarian cancer: A review. Cancer Biol Med 14: 9-32, 2017.
4. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC and Correa CN: Pathology and classification of ovarian tumors. Cancer 97 (Suppl 10): S2631-S2642, 2003.
5. Pratt J: New insights into ovarian cancer pathology. Ann Oncol 23 (Suppl 10): x111-x117, 2012.
6. Peres LC, Cushing-Haagen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, et al: Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol 151: 53-60, 2018.
7. Duska LR and Kohn EC: The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol 28 (Suppl 8): viii8-viii12, 2017.
8. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wibmerger P, Hauptmann S and Schouli J: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet 293: 695-700, 2016.
9. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al: Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15: 668-679, 2015.
10. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin F, Alsop K, Bailey PJ, et al: Whole-genome characterization of chemoresistant ovarian cancer. Nature 521: 499-494, 2015.
11. Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, et al: Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 6: 37663-37677, 2015.
12. Wilbur MA, Shih IM, Segars JH and Fader AN: Cancer implications for patients with endometriosis. Semin Reprod Med 35: 110-116, 2017.
13. Munksgaard PS and Blaakaer J: The association between endometriosis and gynecological cancers and breast cancer: A review of epidemiological data. Gynecol Oncol 123: 157-163, 2011.
14. Yiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConney MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
15. Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogasawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih iM: Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 22: 1310-1315, 2012.
16. Hollis RL and Gourley C: Genetic and molecular changes in ovarian cancer. Cancer Biol Med 13: 236-247, 2016.
17. Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, Zheng J, Fasching P, Zheng W, et al: Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med 16: e1002893, 2019.
18. La Vecchia C: Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev 26: 55-62, 2017.
19. Liao Y, Tu C, Song X and Cai L: Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. J Assist Reprod Genet 37: 1489-1495, 2020.
20. Daly MB, PaI T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkanany A, Friedman S, Goggins M, Hutton ML, et al: Genetic/Familial high-risk assessment: Breast, ovarian, and pancreatic cancer. Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19: 77-102, 2021.

21. Onwude J: Hormone therapy and ovarian cancer. Lancet 386: 1037-1038, 2015.

22. Marsch LS, Lokkegaard E, Andreasen AH, Krüger-Kjaer S and Lidegaard O: Hormone therapy and ovarian cancer. JAMA 302: 296-305, 2009.

23. Colombo N, Sessa C, du Bois A, Ledermann J, McCloggure WG, Nechisch I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al: ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced disease, borderline tumours and recurrent disease. Ann Oncol 30: 672-705, 2019.

24. Saeib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R and Risch HA, Marrett LD, Jain M and Howe GR: Differences in risk cancer. Best Pract Res Clin Obstet Gynaecol 41: 3-14, 2017.

25. Gass ML, Cardenas C, Alvero AB, Yun BS and Mor G: Redefining the Metabolism 86: 1-2, 2018.

26. Endocr Relat Cancer 23: R411-R422, 2016.

27. Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer: A predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 110: 207-210, 2003.

28. Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41: 3-14, 2017.

29. Risch HA: Hormonal etiology of epithelial ovarian cancer, with prospective study of US women. JAMA 285: 1460-1465, 2001.

30. Rizkallah I, Serrano‑Sanchez R and de la Rosette‑Janssen N: Hormone replacement therapy and ovarian cancer mortality in a large cancer. Anticancer Res 29: 37-42, 2008.

31. Hathwa MF: Incessant ovulation‑a factor in ovarian neoplasia? Lancet 2: 163, 1971.

32. Fleming JS, Beaujég CR, Haviv I, Chenex‑Trench G and Tan OL: Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Mol Cell Endocrinol 247: 4-21, 2006.

33. Hathwa MF: Incessant ovulation and ovarian cancer—a hypothesis revisited. Facts Views Vis Obgyn 5: 292-297, 2013.

34. Peres LC, Moorman PG, Alberg AJ, Bandera EV, Barnholz‑Sloan J, Bondy M, Cote ML, Funkhouser E, Peters ES, Schwartz AG, et al: Lifetime number of ovariatory cycles and epithelial ovarian cancer risk in African American women. Cancer Causes Control 28: 405-414, 2017.

35. Yang HP, Murphy KR, Pfeiffer RM, George N, Garcia‑Closas M, Lissowska J, Brauton LA and Wenztenz N: Lifetime number of ovariatory cycles and risk of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 183: 800-814, 2016.

36. Mizushima T and Miyamoto H: The role of androgen receptor signaling in ovarian cancer. Cells 8: 176, 2019.

37. Gibson DA, Smitsidellis I, Collins F and Saunders PT: Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer 21: T203-T212, 2014.

38. Kollara A, Shathasivam P, Park S, Ringuezette MJ and Brown TJ: Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation. J Steroid Biochem Mol Biol 196: 104-109, 2019.

39. Huang SL, Chang TC, Cao CCK and Sun NK: Role of the TLR4‑androgen receptor axis and genistein in taxol‑resistant ovarian cancer cells. Biochem Pharmacol 177: 11395, 2020.

40. Feng D, Zhao T, Yan K, Liang H, Liang J, Zhou Y, Zhao W and Ling B: Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2‑dependent pathway. Oncol Rep 38: 1091-1098, 2017.

41. Parrott JA, Doraiswamy V, Kim G, Mosher R and Skinner MK: Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172: 213-222, 2001.

42. Zheng W, Magid MS, Kramer EE and Chen YT: Follicle‑stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148: 475-503, 1996.

43. Chambers GM, Sullivan EA, Ishihara O, Chapman MG and Adamson GD: The economic impact of assisted reproductive technology: A review of selected developed countries. Fertil Steril 91: 2281-2294, 2009.

44. Pawlikowski Łodź M: Expression of follicle stimulating hormone receptors in intra‑tumoral vasculature and in tumoral cells—the involvement in tumour vascularization and the perspectives of application in cancer diagnosis and therapy. Endokrynol Pol 46: 223, 2021.
63. Cheung J, Lokman NA, Abraham RD, Macpherson AM, Lee E, Grutzner F, Dhima N, Oehler MK and Ricciardelli C: Reduced gonadotropin receptor expression is associated with a more aggressive ovarian cancer phenotype. Int J Mol Sci 22: 7, 2020.

64. Lin MT, Wong AS and Leung PC: Gonadotropin induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostat glandin E(2) production in human ovarian cancer cells. Endocrinology 151: 2985-2993, 2010.

65. Song K, Dai L, Long X, Wang W and Di W: Follicle-stimulating hormone promotes the proliferation of ovarian endometriosis cords from ovarian cancer cells by activating sphingosine kinase. Sci Rep 10: 13834, 2020.

66. Warrenfeltz SW, Lott SA, Palmer TM, Gray JC and Puett D: Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. Int J Gynecol Cancer 23: 1785-1788, 2008.

67. Liao H, Zhou Q, Gu Y, Duan T and Feng Y: Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 27: 1873-1878, 2012.

68. Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol 155: 69-74, 2011.

69. Sakai T, Shiraishi A, Kawada T, Matsubara S, Aoyama M and Satake H: Invertebrate Gonadotropin-releasing hormone-related peptides and their receptors: An update. Front Endocrinol (Lausanne) 8: 217, 2017.

70. Jankowska AG, Andrusiewicz M, Fischer N and Warchol PJ: Expression of hCG and GnRHS and their receptors in endometrial carcinoma and hyperplasia. Int J Gynecol Cancer 20: 101-107, 2010.

71. Gründker C, Schlottaw L, Viereck V, Eicke N, Horst A, Kairies B and Emmons G: Antiproliferative effects of the GnRH antagonist cetrorelix on human endometrial cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151: 141-149, 2004.

72. Kang SK, Tai CJ, Cheng KW and Leung PC: Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells. Mol Cell Endocrinol 170: 143-151, 2000.

73. Gründker C, Günther AR, Millar RP and Emmons G: The role of gonadotropin-releasing hormone receptor-type I expression in the development of an aggressive ovarian cancer phenotype. Int J Mol Sci 22: 71, 2020.

74. Calvert AH, Robson CN and Edmondson RJ: Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells. Anticancer Res 21: 2369-2380, 2001.

75. Peng C, Bai J, Oehler MK and Ricciardelli C: GnRH receptors: Function and relative role. Trends Endocrinol Metab 10: 12-20, 1999.

76. Newton CL, Riekert C and Millar RP: Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol 70: 497-515, 2018.

77. Newton CL, Riekert C and Millar RP: Therapeutic neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic-pituitary-gonadal axis. Endocr Dev 30: 106-129, 2016.

78. Wuntakal R, Seshadri S, Montes A and Lane G: Luteinizing hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 2016: CD011322, 2016.

79. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martinelli L and Moretti RM: GnRH receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr Rev 33: 784-811, 2012.

80. Gründker C, Günther AR and Emmons G: The effect of gonadotropin-releasing hormone analogues in the inhibition of ovarian cancer transfected tumors and in the protection of ovarian function after chemotherapy on nude mice. Zhonghua Fu Chan Ke Za Zhi 46: 892-897, 2011 (In Chinese).

81. Gründker C, Völker P, Schulz KD and Emmons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers. Frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186: 171-179, 2002.

82. Gründker C, Völker P and Emmons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(1)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142: 2369-2380, 2001.

83. Gründker C, Völker P, Schulz KD and Emmons G: Luteinizing hormone-releasing hormone agonist tiotropil and antagonist cetrorelix inhibit EGFr-induced c-fos expression in human gyne- cological cancers. Gynecol Oncol 78: 194-202, 2000.

84. Engeli JB, Jahnke JC, Häusler SF, Meyer S, Segerer SE, Diessner J, Dietl J and Honig A: Peptidomimetic GnRH antago- nist AEZS-115 inhibits tumor growth in human endometrial cancer cells. Anticancer Res 32: 2063-2068, 2012.

85. Günthert AR, Gründker C, Hollmann K and Emmons G: Luteinizing hormone-releasing hormone induces Jun-D-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 294: 11-15, 2002.

86. Imai A, Takagi A, Horibe S, Takagi H and Tamaya T: Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: Possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 83: 427-431, 1998.

87. Imai A, Takagi A, Horibe S, Takagi H and Tamaya T: Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: Possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 83: 427-431, 1998.

88. Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP and Langdon SP: Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-xb survival signatures following GnRH receptor activation. Endocr Relat Cancer 20: 2369-2380, 2013.

89. Mo Y, Peng Z, Zhou H, He Z, Huang L and Yang D: Regulation of gonadotropin-releasing hormone (GnRH) receptor-I expression in the pituitary and ovary by a GnRH agonist and antagonist. Reprod Sci 17: 68-77, 2010.

90. Gründker C, Schulz K, Günther AR and Emmons G: Luteinizing hormone-releasing hormone induces nuclear factor kappa B activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85: 3815-3820, 2000.

91. Gründker C, Günther AR, Millar RP and Emmons G: Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87: 1427-1430, 2002.

92. Fister S, Günther AR, Aicher B, Paulini KW, Emmons G and Gründker C: GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 69: 6473-6481, 2009.

93. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR and Millar RP: A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 14q.12. Endocrinology 144: 423-436, 2003.

94. Neil JD, Musgrove LC and Duck LW: Newly recognized peptides and their receptors: An update. Front Endocrinol (Lausanne) 8: 236, 2017.

95. Gründker C, Schulz K, Günther AR and Emmons G: Luteinizing hormone-releasing hormone induces nuclear factor kappa B activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85: 3815-3820, 2000.

96. Gründker C, Günther AR, Millar RP and Emmons G: Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87: 1427-1430, 2002.

97. Gründker C, Schulz K, Günther AR and Emmons G: Luteinizing hormone-releasing hormone induces nuclear factor kappa B activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85: 3815-3820, 2000.
Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Carnino F, Iskra L, Fuda G, Foglia G, Odicino F, Bruzzone M, Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Hanker L, Hilpert F, Sindermann H, Gründker C and Harter P: Group (AGO GYN 5). Gynecol Oncol 133: 427‑432, 2014.

LHRH receptors: A multicenter phase II trial of the ago‑study with platinum refractory or resistant ovarian cancer expressing acetate) an LHRH agonist linked to doxorubicin in women. Efficacy and safety of a GnRH analog in ovarian carcinoma. An EORTC gynecologic cancer Co‑operative group study. Anticancer Drugs 12: 159‑162, 2001.

Emons G, Ortman O, Teichert HM, Fassl H, Löhrs U, Kullander S, Carmela A, Alyanon D and Oberheuser F: Luteinizing hormone‑releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapetyl Ovarian Cancer Study Group. Cancer 78: 1452‑1460, 1996.

Jäger W, Sauerbrei W, Beck E, Maessen V, Stumppe M, Meier W, Kuhn W and Janicke F: A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Br J Cancer 105: 2639‑2642, 1997.

S渭la H, Barben H, Fritz R, Baranda M, Salzer H, Baur M and Dietrich C: Goserelin as a GnRH‑anologue as third‑line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer 2: 160‑162, 1992.

Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmonds DM, Carmela J and Harris AL: A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 65: 621‑623, 1992.

Hasan J, Ton N, Mullahitha S, Clamp A, McNeilly A, Marshall E and Jayson GC: Phase II trial of tamoxifen and goserelin in recurrent ovarian carcinoma. Br J Cancer 93: 647‑651, 2005.

Marinacci M, D’Addario V, Serrati A, Pinto V and Cagnazzo G: Leuprolide acetate as a salvage‑therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol 17: 286‑288, 1996.

Paskeviciute L, Roed H and Engelholm S: No rules without exception: Long‑term complete remission observed in a study using a LH‑RH agonist in platinum‑refractory ovarian cancer. Gynecol Oncol 86: 297‑301, 2002.

du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bavinck T, Olbricht S, Jacksch C, et al: Chemothoerapy as hormon therapy in platinum‑ and Paclitaxel‑refractory ovarian cancer: A randomised trial of the german arbeitsgemeinschaft gynäkologische onkologie (AGO) study group ovarian cancer. Ann Oncol 13: 251‑257, 2002.

Balbi G, Piano LD, Cardone A and Cirelli G: Second‑line therapy of ovarian cancer with GNRH analogs. Int J Gynecol Cancer 14: 799‑803, 2004.

Kavanagh JJ, Roberts W, Townsend P and Hewitt S: Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 7: 115‑118, 1989.

Bruckner HW and Motwani BF: Treatment of advanced refractory ovarian carcinoma with a gonadotropin‑releasing hormone hormone. J Obest Gynecol 161: 1216‑1218,1989.

Miller DS, Brady MF and Barrett RJ: A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Obest Gynecol Oncol 15: 125‑128, 1992.

Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Vöker P, Kavanagh J, Steger M, Schulz KD and Emons G: Phase II study of cetrotrexil, a luteinizing hormone‑releasing hormone antagonist in patients with platinum‑resistant ovarian cancer. Gynecol Oncol 90: 552‑559, 2003.

Parmar H, Rustin G, Lightman SL, Phillips RH, Hanham IW and Schally AV: Response to D‑Trp‑6‑luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian carcinoma. J Clin Oncol Res 296: 1229‑128, 1988.

Emons G, Gorchev G, Sehouli J, Wimmerberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründler C and Harter P: Efficacy and safety of AEZS‑108 (INN: Zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer treating LH‑RH receptors: A multicenter phase II trial of the ago‑study group (AGO GYN 5). Gynecol Oncol 133: 427‑432, 2014.

Med M, Peters‑Engel C, Fuchs G and Leodolter S: Triptorelin (D‑Trp‑6‑LHRH) in combination with carboplatin‑containing polychemotherapy for advanced ovarian cancer: A pilot study. Anticancer Res 13: 233‑237, 1993.

Falkson CF, Falkson HC and Falkson G: Cisplatin versus cisplatin plus D‑Trp‑6‑LHRH in the treatment of ovarian cancer. A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology 53: 313‑317, 1996.

Rzepka‑Gőrska I, Dudecka‑Glaz A, Kosmider M and Malek P: GnRH analogue as an adjuvant therapy for ovarian cancer patients. Int J Gynaecol Obstet 81: 199‑205, 2003.

Mizushima T, Tirador K and Miyamoto H: Androgen receptor activation: A prospective therapeutic target for bladder cancer? Expert Opin Ther Targets 21: 249‑257, 2017.

Fujii Y, Kim T and Kato M: Androgen receptor modulators: A review of recent patents and reports (2012‑2018). Expert Opin Ther Pat 29: 439‑453, 2019.

Gucalp A and Traina TA: The androgen receptor: Is it a promising target? Ann Surg Oncol 24: 2876‑2880, 2017.

Ueda T, Mawi NR, Bruchovsky N and Sadar MD: Ligand‑independent activation of the androgen receptor by interleukin‑6 and the role of steroid receptor coactivator‑1 in prostate cancer cells. J Biol Chem 277: 38087‑38094, 2002.

Pagliarulo A: Androgen deprivation therapy for prostate cancer. Expert Opin Biol Ther 10: 509‑510, 2010.

Rahim B and O’Regan R: AR Signaling in breast cancer. Cancers (Basel) 9: 21, 2017.

Antonarakis ES: AR Signaling in human malignancies: Prostate cancer and beyond. Cancers (Basel) 10: 25, 2018.

Hamilton TC, Davies P and Grifiths K: Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol 90: 421‑431, 1981.

Kühnel R, de Graaff J, Rao BR and Stolk JG: Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 26: 393‑397, 1987.

Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC and van der Kwast TH: An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 24: 90‑95, 1993.

Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN and Edmondson RJ: Androgen‑related expression of G‑proteins in ovarian cancer. Br J Cancer 101: 498‑503, 2009.

Cardillo MR, Petrangeli A, Aliotta N, Salvatori L, Ravenna L, Chang C and Castagna G: Androgen receptors in ovarian tumors: Correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17: 231‑237, 1998.

Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN and Edmondson RJ: Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 124: 142‑147, 2017.

de Toledo MC, Sarian LO, Sallum LF, Andrade LL, Vassallo J, de Paiva Silva GR, Pinto GA, Soares FA, Fonseca CD and Derchain SF: Analysis of the contribution of immunologically‑detectable HER2, steroid receptors and of the ‘triple‑negative’ tumor status to disease‑free and overall survival of women with epithelial ovarian cancer. Acta Histochec 116: 440‑447, 2014.

Jönsson JM, Arildsen NS, Malander S, Måsbäck H, Hartman L, Nilbert M and Hedenfalk I: Sex Steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol 8: 424‑433, 2015.

Butler MS, Ricciardiello C, Tilley WD and Hickey TE: Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Horm Cancer 4: 154‑164, 2013.

Edmondson RJ, Monaghan JM and Davies BR: The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 86: 879‑885, 2002.

Sawd S, Ulinski G, Mok C, Hu GK and Ho SM: Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61: 6768‑6776, 2001.

Nourbakhsh M, Golestan J, Zahrai M, Mordarssir MH, Malek Z, Karami‑Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol 330: 10‑16, 2010.
144. Bogush TA, Basharina AA, Bogush EA, Ryabinina OM, Tjulandin AS and Tjulandin SA: Estrogen receptors alpha and beta in ovarian cancer: Expression level and prognosis. Dokl Biochem Biophys 482: 243-251, 2013.

150. Sun NK, Huang SL, Lu HP, Chang TC and Chao CC: Integrative cancer: Preclinical and clinical evidence. Cancer Prev Res 110: 2448‑2456, 2007.

161. Catzenellenbogen B and Catzenellenbogen J: Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to synaptic plasticity. Front Endocrinol (Lausanne) 11: 385, 2020.

163. Ghasemi A, Saedi J, Mohtashami M and Hashemy SI: Estrogen-dependent role of ERβ in ovarian cancer progression induced by leptin/Ob-Rb axis. Mol Cell Biochem 458: 207-217, 2019.
184. Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hoppers G and Reyners A: Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol 88: 634-639, 2003.

185. van der Vange N, Greggi S, Burger CW, Kenemans P and Vermorken J: Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 34: 813-820, 1995.

186. Rolski J and Pawlicki M: Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. J Cancer Res Clin Oncol 146: 586-589, 2010.

187. Tropé C, Martí C and Kaern J: Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 36 (Suppl 4): S59-S61, 2000.

188. Van Der Velden J, Gitsch G, Wain GV, Friedlander ML and Hacker NF: Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 5: 301-305, 1995.

189. Aflgren JD, Ellison NM, Gottlieb RJ, Lulana F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D, et al: Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic oncolo­gic program. J Clin Oncol 11: 1957-1963, 1993.

190. Jakobsen A, Bertelsen K and Sell A: Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol 23: 915-916, 1987.

191. Pagel JC and Thorpe S: Treatment of advanced ovarian carcinoma with tamoxifen: A phase II trial. Proc 2nd Eur Conf Clin Oncol: May 29, 1983 (Epub ahead of print).

192. Osborne RJ, Malik ST, Slevin ML, Harvey VJ, Spona J, Salter H and Williams CJ: Tamoxifen in refractory ovarian cancer: The use of a loading dose schedule. Br J Cancer 57: 115-116, 1988.

193. Slevin ML, O’Riordan IJ, Osborne RJ, Shepherd JH, Williams CJ and Mead GM: A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 22: 309-312, 1986.

194. Shiery DR, Kavanagh JJ Jr, Gershenson DM, Freedman RS, Copeland LJ and Jones LA: Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 66: 575-578, 1985.

195. Hatch KD, Beecham JB, Blessing JA and Creasman WT: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68: 269-271, 1991.

196. Weimer SA, Alberts DS, Surwit EA, Davis J and Grosso D: Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 27: 208-213, 1987.

197. Schwartz PE, Keating G, MacLusky N, Naftolin F and Eisenfeld A: Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 59: 583-588, 1982.

198. George A, McLachlan J, Tunariu N, Delha P, Migali C, Gore M, Kaye S and Banerjee S: The role of hormonal therapy in patients with relapsed high-grade ovarian cancer: A retrospective series of tamoxifen and letrozole. BMC Cancer 17: 456, 2017.

199. Huhau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivankov I, Tewari KS, Mannell RS, Zanotti K and Benbrook DM: Randomized phase III trial of tamoxifen versus thalidomide in women with biochemically-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane-based chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 119: 438-444, 2001.

200. Markman M, Webster K, Van der Velden J, Peterson G, Kulp B and Belinson J: Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 94: 404-408, 2004.

201. Wagner U, du Bois A, Pfisterer J, Huber J, Loibl S, Liick HJ, Sehouri J, Groppi M, Stähle A, Schmallfeldt B, et al: Gefitinib in combination with tamoxifen in patients with ovarian cancer resistant to platinum-based chemotherapy - results of a phase II study. Int J Gynecol Cancer 11: 438-444, 2001.

202. Fader AN, Bergstrom J, Jernigan A, Tanner EL, Roche KL, Stone RL, Levinson KL, Ricci S, Wethington S, Wang TL, et al: Primary cytoreductive surgery and adjuvant hormonal mono­therapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol 152: 278-285, 2019.

203. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A and Sun CC: Hormonal maintenance therapy for women with low-grade serous carcinoma of the ovary or peritoneum. J Clin Oncol 35: 1103-1111, 2017.

204. Lippis RL, Nunes H, Towler J, Yen X, Rye T, Dansky P, Richmond MJ, Russey F, Churchman M, et al: Endocrine treatment of high grade serous ovarian carcinoma: Multicenter clinical trial of a novel approach to therapy. Gynecol Oncol 152: 278-285, 2019.

205. Schwartz PE, Keating G, MacLusky N, Naftolin F and Eisenfeld A: Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 59: 583-588, 1982.

206. Krasner CN, Debernardo RL, Findley M, Penen R, Campos S, Roche M and Seiden MV: Phase II trial of anastrozole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol 23 (Suppl 16): S1121. 2005.

207. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstratiou E, Grani S, Hamilos G, Zorzou M and Dimopoulou MA: Hormonal therapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 104: S1121, 2007.

208. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, and Gershenson DM: Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 110: 56-59, 2008.

209. Smyth JF, Gourley C, Walker G, MacKean J, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, et al: Anti-estrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622, 2007.

210. van der Velden J, Gitsch G, Wain GV, Friedlander ML and Hacker NF: Tamoxifen therapy for ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol 23: 915-916, 1987.

211. Perez-Gracia JL and Carrasco EM: Tamoxifen therapy for advanced low-grade serous ovarian carcinoma. J Clin Oncol 119: 444-450, 2010.
241. Xie YL, Yang YJ, Tang C, Sheng HJ, Jiang Y, Han K and Pelegrina LT, de Los Ángeles Sanhueza M, Ramona Cáceres AR, Peluso JJ: Progesterone signaling mediated through progesterone receptor membrane component-1. J Clin Endocrinol Metab 95: S5-S11, 2010.

242. Lee YJ, Shin YJ, Kim HS, Heo Ji, Kho YJ, Kang HJ, Park SH and Lee YJ: Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells. Gynecol Oncol Rep 27: 47-52, 2020.

243. Shin YY, Kang EJ, Jeong JS, Kim MJ, Jung EM, Jeung EB and An BS: Pregnenolone as a potential candidate for hormone therapy for female reproductive disorders targeting ERβ. Mol Reprod Dev 86: 109-117, 2019.

244. Federman E, Gomora MJ, Morales-Vázquez F, Pérez-Montiel D and Mendez C: Progesterone receptor membrane component-1: Expression in breast, uterine, and ovarian cancers. J Mol Endocrinol 54: R31-R53, 2015.

245. Miesesio ND, Wozniak BK and Lyndon JP: Progesterone receptor-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68: 771-778, 2003.

246. Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA and Lange CA: Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 12: 1433-1449, 2013.

247. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A and Sasano H: Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: Immunohistochemical and RT-PCR studies. Br J Cancer 37: 1488-1494, 2000.

248. Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yasgushi N and Sasano H: Differential expression of progesterone receptor isoforms A and B in the normal ovary, and high-grade serous and endometrial, and malignant ovarian tumors. Jpn J Cancer Res 93: 807-815, 2002.

249. Lenhard M, Tereza L, Heubelin S, Ditsch N, Hims I, Mayr D, Tsatsaronis G, Mangelis A, Williams TA, Jernigan LM, McEwen BS and Volytsis HS: Let-7a and miR-34b in ovarian cancer cells. Clin Transl Oncol 16: 898-905, 2014.

250. Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA and Lange CA: Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 12: 1433-1449, 2013.
263. Niwa K, Onogi K, Wu Y, Mori H, Harrigan RC and Tamaya T: Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: A pilot study. Eur J Gynaecol Oncol 29: 252-255, 2008.

264. Zheng H, Kavanagh JJ, Hu W, Liao Q and Fu S: Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17: 325-338, 2007.

265. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M and Greggi S: Conservative treatment of early endometrial cancer: Preliminary results of a pilot study. Gynecol Oncol 120: 43-46, 2011.

266. Bonaventura A, O’Connell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, et al: Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer. Int J Gynecol Cancer 27: 900-906, 2017.

267. Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN and Dana WJ: Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: A phase II study. Cancer Treat Rep 70: 369-373, 1986.

268. Greiser CM, Greiser EM and Dören M: Menopausal hormone therapy and risk of ovarian cancer: Systematic review and meta-analysis. Hum Reprod Update 13: 453-463, 2007.

269. Beral V, Bull D, Green J and Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703-1710, 2007.

270. Koskela-Niska V, Lyytinen H, Riska A, Pukkala E and Ylikorkala O: Ovarian cancer risk in postmenopausal women using estradiol-progesterin therapy—a nationwide study. Climacteric 16: 48-53, 2013.

271. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y and Brinton LA: Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107: 1181-1187, 2012.

272. Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK and Lidegaard O: Hormone therapy and different ovarian cancers: A national cohort study. Am J Epidemiol 175: 1234-1242, 2012.

273. Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, Zhang J, Meng Y and Lin J: Menopausal hormone replacement therapy and the risk of ovarian cancer: A meta-analysis. Front Endocrinol (Lausanne) 10: 801, 2019.

274. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G and Peto R: Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet 385: 1835-1842, 2015.

275. Wen Y, Huang H, Huang H, Wu M, Shen K and Pan L: The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric 16: 673-681, 2013.

276. Li D, Ding CY and Qiu LH: Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. Gynecol Oncol 139: 355-362, 2015.